<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Int J Surg</journal-id><journal-id journal-id-type="iso-abbrev">Int J Surg</journal-id><journal-id journal-id-type="pmc-domain-id">2035</journal-id><journal-id journal-id-type="pmc-domain">lwwopen</journal-id><journal-id journal-id-type="publisher-id">JS9</journal-id><journal-title-group><journal-title>International Journal of Surgery (London, England)</journal-title></journal-title-group><issn pub-type="ppub">1743-9191</issn><issn pub-type="epub">1743-9159</issn><custom-meta-group><custom-meta><meta-name>pmc-is-collection-domain</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-collection-title</meta-name><meta-value>Lippincott Open Access</meta-value></custom-meta></custom-meta-group></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12430773</article-id><article-id pub-id-type="pmcid-ver">PMC12430773.1</article-id><article-id pub-id-type="pmcaid">12430773</article-id><article-id pub-id-type="pmcaiid">12430773</article-id><article-id pub-id-type="pmid">40540293</article-id><article-id pub-id-type="doi">10.1097/JS9.0000000000002715</article-id><article-id pub-id-type="publisher-id">IJS-D-25-01214</article-id><article-version-alternatives><article-version article-version-type="pmc-version">1</article-version><article-version vocab="JAV" vocab-identifier="http://www.niso.org/publications/rp/RP-8-2008.pdf" article-version-type="Version of Record">3</article-version></article-version-alternatives><article-categories><subj-group subj-group-type="heading"><subject>Tumour Marker Prognostic Study</subject></subj-group></article-categories><title-group><article-title>Intratumoral and peritumoral habitat radiomics of MRI predicts pathologic complete response to neoadjuvant chemoimmunotherapy in oral squamous cell carcinoma</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Yuan</surname><given-names initials="Z">Zilong</given-names></name><degrees>MD</degrees><email>yuanzilong0213@126.com</email><xref rid="aff1" ref-type="aff">
<sup>a</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0009-0000-7334-0581</contrib-id><name name-style="western"><surname>Ai</surname><given-names initials="S">Shuangquan</given-names></name><degrees>MD</degrees><xref rid="aff1" ref-type="aff">
<sup>a</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>He</surname><given-names initials="Q">Qian</given-names></name><degrees>MD</degrees><xref rid="aff2" ref-type="aff">
<sup>b</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Wu</surname><given-names initials="K">Kun</given-names></name><degrees>MD</degrees><xref rid="aff3" ref-type="aff">
<sup>c</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Yang</surname><given-names initials="M">Miao</given-names></name><degrees>MS</degrees><email>570538045@qq.com</email><xref rid="aff1" ref-type="aff">
<sup>a</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Zheng</surname><given-names initials="K">Kaiyi</given-names></name><degrees>MD</degrees><email>1543267643@qq.com</email><xref rid="aff4" ref-type="aff">
<sup>d</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>He</surname><given-names initials="Y">Yaoyao</given-names></name><degrees>MD</degrees><xref rid="aff1" ref-type="aff">
<sup>a</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Tang</surname><given-names initials="X">Xiaojuan</given-names></name><degrees>MD</degrees><email>TangXiaojuan-1@163.com</email><xref rid="aff5" ref-type="aff">
<sup>e</sup>
</xref></contrib><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Liu</surname><given-names initials="Y">Yulin</given-names></name><degrees>PhD</degrees><email>liuyl26@163.com</email><xref rid="aff1" ref-type="aff">
<sup>a</sup>
</xref><xref rid="COR0001" ref-type="corresp">*</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Wu</surname><given-names initials="Z">Zheng</given-names></name><degrees>PhD</degrees><xref rid="aff2" ref-type="aff">
<sup>b</sup>
</xref><xref rid="COR0001" ref-type="corresp">*</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Wu</surname><given-names initials="Y">Yuan</given-names></name><degrees>PhD</degrees><xref rid="aff3" ref-type="aff">
<sup>c</sup>
</xref><xref rid="COR0001" ref-type="corresp">*</xref></contrib><aff id="aff1"><label>a</label>Department of Radiology, Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan. Hubei, China</aff><aff id="aff2"><label>b</label>Department of Radiation Oncology, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University &amp; Hunan Cancer Hospital, Changsha, Hunan, China</aff><aff id="aff3"><label>c</label>Department of Radiation and Oncology, Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan. Hubei, China</aff><aff id="aff4"><label>d</label>College of Biomedical Engineering, South-Central Minzu University,Wuhan, Hubei, China,</aff><aff id="aff5"><label>e</label>Department of Radiologic Center, Renmin Hospital, Hubei University of Medicine, Shiyan, Hubei, China</aff></contrib-group><author-notes><corresp id="COR0001"><label>*</label>Corresponding authors. Address: Department of Radiology, Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology, No. 116 Zhuodaoquan South Load, Hongshan District, Wuhan, Hubei 430079, China. Tel.: (86) 027-8767985. E-mail: <email>liuyl26@163.com</email> (Y. Liu); Department of Radiation Oncology, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University &amp; Hunan Cancer Hospital, E-mail: <email>wuzheng@hnca.org.cn</email> (Z. Wu); Department of Radiology, Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology, No. 116 Zhuodaoquan South Load, Hongshan District, Wuhan, Hubei 430079, China. Tel.: (86) 027-87670063. E-mail: <email>gwgfe@163.com</email> (Y. Wu).</corresp></author-notes><pub-date pub-type="collection"><month>9</month><year>2025</year></pub-date><pub-date pub-type="epub"><day>20</day><month>6</month><year>2025</year></pub-date><volume>111</volume><issue>9</issue><issue-id pub-id-type="pmc-issue-id">496813</issue-id><fpage>6232</fpage><lpage>6244</lpage><history><date date-type="received"><day>05</day><month>3</month><year>2025</year></date><date date-type="accepted"><day>30</day><month>5</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>12</day><month>09</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>13</day><month>09</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-09-13 17:25:36.317"><day>13</day><month>09</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>Copyright &#169; 2025 The Author(s). Published by Wolters Kluwer Health, Inc.</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article distributed under the <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License 4.0</ext-link> (CCBY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="js9-111-6232.pdf"/><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="js9-111-6232.pdf"/><abstract><sec><title>Background:</title><p>Neoadjuvant chemoimmunotherapy (NACI) shows promise in oral squamous cell carcinoma (OSCC), but reliable noninvasive biomarkers for predicting pathologic complete response (pCR) remain scarce. Radiomics integrating intratumoral and peritumoral heterogeneity across multi-sequence MRI may offer novel insights into treatment response evaluation.</p></sec><sec><title>Methods:</title><p>The data of 212 patients with OSCC after NACI were retrospectively collected and analyzed. Among these patients, 56 (26.4%) achieved pCR after NACI. Intratumoral and peritumoral habitat imaging (HI) was achieved using the K-means clustering algorithm applied to T1-weighted imaging (T1WI), axial T2-weighted imaging with fat suppression (T2WI), and contrast-enhanced T1-weighted imaging with fat suppression (T1C). Moreover, intratumoral and peritumoral HI models were constructed and compared using the receiver operating characteristic curve (ROC). Five-fold cross-validation was performed to mitigate model overfitting.</p></sec><sec><title>Results:</title><p>Intratumoral HI models derived from different sequences and the Intratumoral Fusion model exhibited favorable predictive ability, with AUCs of 0.738-0.817 and 0.729-0.789 in the training and testing cohorts, respectively. Moreover, peritumoral HI models displayed marginally higher predictive abilities compared to intratumoral HI and Fusion models, with AUCs of 0.734-0.869 and 0.788-0.802 in the training and testing cohorts, respectively. Meanwhile, the decision model with peritumoral habitat features (PHF<sub>S</sub>), intratumoral habitat features (IHF<sub>S</sub>), and 3 clinical features displayed the highest performance, with average AUCs of 0.913 and 0.843 in both respective cohorts. Among the most important features screened by SHAP, three IHFs and one PHF could effectively distinguish between the lower and higher groups of programmed cell death ligand 1 (PD-L1) Combined Positive Score (t&#160;=&#160;2.027-2.275, <italic toggle="yes">P</italic> &lt; 0.05), whilst two PHFs were highly correlated with CD45+&#160;white blood cell densities in the stroma (r&#160;=&#160;0.958,&#160;&#8722;0.920, <italic toggle="yes">P</italic> &lt; 0.05), which were associated with pCR.</p></sec><sec><title>Conclusions:</title><p>Integrated intratumoral and peritumoral HI derived from multi-sequence MRI offers a high predictive capacity for pCR following NACI in OSCC patients.</p></sec></abstract><kwd-group><kwd>habitat imaging</kwd><kwd>intratumoral and peritumoral</kwd><kwd>oral squamous cell carcinoma</kwd><kwd>pathologic complete response</kwd><kwd>radiomics</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>OPEN-ACCESS</meta-name><meta-value>TRUE</meta-value></custom-meta><custom-meta><meta-name>SDC</meta-name><meta-value>T</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro"><title>Introduction</title><p>As is well documented, oral squamous cell carcinoma (OSCC) is a relatively prevalent malignant tumor among head and neck squamous cell carcinoma (HNSCC)[<xref rid="R1" ref-type="bibr">1</xref>] and is characterized by a poor prognosis. To date, its treatment is largely similar to that of HNSCC. The predominant treatment strategy for HNSCC patients is a comprehensive regimen integrating surgery, radiotherapy, chemotherapy, and targeted therapy. However, a substantial proportion of patients, approximately 40%-60%, ultimately experience local recurrence or distant metastasis, with a 5-year survival rate below 50%[<xref rid="R2" ref-type="bibr">2</xref>]. In recent years, immunotherapy, especially immune checkpoint inhibitors (ICIs), has emerged as a promising approach for the treatment of OSCC. Although neoadjuvant chemoimmunotherapy (NACI) can significantly enhance the pathologic complete response (pCR) rate in patients with locally advanced HNSCC, including those with OSCC, roughly 45% of patients fail to achieve pCR[<xref rid="R3" ref-type="bibr">3</xref>]. Consequently, there is an urgent and unmet need for the early prediction of NACI efficacy in OSCC patients.</p><p>Radiomics, a method for quantifying intratumoral heterogeneity (ITH), has been extensively utilized in diverse aspects of HNSCC<sup>[<xref rid="R4" ref-type="bibr">4</xref>-<xref rid="R14" ref-type="bibr">14</xref>]</sup>. In the specific subfield of OSCC, earlier studies have also focused on its value in predicting staging[<xref rid="R15" ref-type="bibr">15</xref>], cervical lymph node metastasis<sup>[<xref rid="R16" ref-type="bibr">16</xref>-<xref rid="R20" ref-type="bibr">20</xref>]</sup>, local recurrence[<xref rid="R21" ref-type="bibr">21</xref>], bone invasion[<xref rid="R22" ref-type="bibr">22</xref>], and overall survival (OS)[<xref rid="R23" ref-type="bibr">23</xref>].Regarding the prediction of treatment response in OSCC after NACI, only Liu <italic toggle="yes">et al</italic>[<xref rid="R14" ref-type="bibr">14</xref>] attempt to predict post-treatment pCR in HNSCC patients by extracting histogram-related features within tumors from multi-sequence MRI. Nonetheless, it is worth acknowledging that their sample size was limited. Similarly, Lin <italic toggle="yes">et al</italic>[<xref rid="R12" ref-type="bibr">12</xref>] developed a radiomics model based on multi-sequence MRI to predict post-treatment pCR in HNSCC patients, albeit using the traditional radiomics approach. Traditional radiomics typically assumes a homogeneous distribution of features within the region of interest (ROI), thereby overlooking intratumoral regional disparities and facing challenges in capturing the complex spatial distribution information within tumors.</p><p>In contrast, sub-region-based habitat imaging (HI) principally combines quantitative image analysis with the underlying tumor pathophysiology. Constructing a &#8220;habitat map&#8221; of the tumor may reveal internal heterogeneity, thereby mirroring tumor growth, drug resistance, pathological grade, and prognosis<sup>[<xref rid="R24" ref-type="bibr">24</xref>-<xref rid="R28" ref-type="bibr">28</xref>]</sup>. Moreover, given that it can more effectively quantify sub-regions that are more relevant to tumor growth or invasiveness, it is superior to a simple whole-tumor analysis. Concurrently, numerous studies have explored the application of peritumoral radiomics features to characterize the microenvironment for predicting patient outcomes<sup>[<xref rid="R29" ref-type="bibr">29</xref>,<xref rid="R30" ref-type="bibr">30</xref>]</sup>. However, these efforts have been predominantly limited to the overall analysis of the peritumoral region, with several studies demonstrating that peritumoral HI can also contribute to enhancing the predictive capacity of the model<sup>[<xref rid="R31" ref-type="bibr">31</xref>-<xref rid="R33" ref-type="bibr">33</xref>]</sup>.</p><p>To the best of our knowledge, no studies have employed intratumoral and peritumoral HI to predict pCR following NACI in OSCC. Therefore, this study aimed to establish intratumoral and peritumoral HI models based on multi-sequence MRI to predict the pCR of OSCC patients after NACI. In addition, an interpretability analysis method was introduced to enhance the biological interpretability of the model. To ensure transparency and reproducibility in radiomics analysis, this study adheres to the Transparency In The Reporting of Artificial Intelligence (TITAN) guideline[<xref rid="R34" ref-type="bibr">34</xref>] .</p></sec><sec sec-type="methods"><title>Methods</title><sec sec-type="subjects"><title>Patients</title><p>This retrospective study was approved by the institutional review board (IRB) of Hunan Cancer Hospital (A) and Hubei Cancer Hospital (B). Due to the retrospective design and use of de-identified data, individual patient consent was waived by the IRB. All patient data, including clinical and imaging information, were anonymized before analysis, with personal identifiers removed and sensitive data encrypted. This study comprehensively reviewed the clinical information of OSCC patients who underwent NACI at two institutions from March 2020 to December 2023. Initially, a total of 244 patients, consisting of 204 patients from Institution A and 40 from Institution B, were identified. Participants were eligible for inclusion if they met the following criteria: (a) histopathologically confirmed OSCC at the initial diagnosis; (b) no treatment received prior to the first MRI examination; (c) receipt of NACI; (d) underwent MRI examination after NACI; (e) Underwent surgical intervention. The exclusion criteria were as follows: (a) Absence of clinical data and postoperative pathological results; (b) MRI image artifacts significantly affecting image quality. Ultimately, the dataset comprised 187 patients from Institute A and 25 patients from Institute B. Among them, 56 achieved pCR, whereas the remaining 156 patients were classified as non-pCR (Fig. <xref rid="F1" ref-type="fig">1</xref>). This study had been reported in line with the REMARK criteria[<xref rid="R35" ref-type="bibr">35</xref>].<boxed-text id="UBT0001" position="float" orientation="portrait"><sec><title>HIGHTLIGHTS</title><p>
<list list-type="bullet"><list-item><p>In a retrospective analysis of 212 OSCC patients undergoing neoadjuvant chemoimmunotherapy, multi-sequence MRI-derived intratumoral and peritumoral habitat imaging demonstrated robust predictive value for pCR.</p></list-item><list-item><p>The integrated decision model combining peritumoral habitat features (PHFs), intratumoral habitat features (IHFs), and clinical characteristics achieved superior predictive performance (AUC 0.913/0.843 in training/testing cohorts), outperforming single-sequence or single-region models.</p></list-item><list-item><p>SHAP-based visualization identified critical habitat features were associated with PD-L1 CPS and CD45+&#160;in the stroma which was correlated with pCR, providing biological interpretability for personalized treatment optimization.</p></list-item></list></p></sec></boxed-text><fig position="float" id="F1" orientation="portrait"><label>Figure 1.</label><caption><p>Flowchart of patient inclusion.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="js9-111-6232-g001.jpg"/></fig>
</p><p>For each patient, baseline characteristics, such as gender, age, smoking history, drinking history, diagnosis of tumor occurrence, pre-treatment TNM staging, baseline hematological index, HPV status, and Programmed Death-Ligand 1 (PD-L1) Combined Positive Score (CPS) were collected from medical records. The number of immunotherapy cycles and TNM staging after neoadjuvant therapy were also collected for analysis. It should be noted that only 33 patients underwent PD-L1 CPS assessment.</p></sec><sec><title>MR examination</title><p>In the present study, all patients underwent head and neck MRI scanning. Specifically, Institution A employed the Siemens 1.5&#160;T MRI scanner (Aera), the General Electric (GE) 1.5&#160;T MRI scanner (optima MR360), and the United Imaging 3&#160;T MRI scanner (uMR780), while Institution B utilized the GE 1.5&#160;T MRI scanner (Signa HDXT) and the United Imaging 3&#160;T MRI scanner (uMR790). Subsequently, axial T1-weighted imaging (T1WI), axial fat-suppressed T2-weighted imaging (T2WI), and axial contrast-enhanced T1-weighted imaging with fat suppression(T1C) were acquired for all patients. These highly standardized imaging sequences play a crucial role in the MRI staging process of OSCC. Among them, T1WI provides excellent anatomical detail, T2WI highlights tissue heterogeneity, and T1C emphasizes tumor angiogenesis. Detailed imaging parameters are presented in Supplemental Digital Content, Table S1 (available at: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://links.lww.com/JS9/E435" ext-link-type="uri">http://links.lww.com/JS9/E435</ext-link>).</p></sec><sec><title>Intratumoral and peritumoral region generation</title><p>Referencing the corresponding T1WI and T2WI images, ROI encompassing the whole tumor across all layers was delineated on T1C images by a radiologist with 10&#160;years of experience. In order to ensure the accuracy of the contour, the contoured area was reviewed by another radiologist with 15&#160;years of experience. Regions of necrosis, hemorrhage, or edema were excluded from the ROIs. Delineation was performed using open-source Slicer software (available at: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://www.slicer.org" ext-link-type="uri">http://www.slicer.org</ext-link>). Next, the Onekey v.2.2.3platform (available at: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://medai.icu/" ext-link-type="uri">http://medai.icu/</ext-link>) was utilized to expand the tumor boundary outward by 3 mm, which was defined as the peritumoral region[<xref rid="R12" ref-type="bibr">12</xref>]. The radiologist with 15&#160;years of experience reviewed the peritumoral region to ensure that the expanded regions excluded surrounding cavities and bone tissues, thereby improving the accuracy and reliability of peritumoral segmentation. The workflow for radiomics analysis is illustrated in Fig. <xref rid="F2" ref-type="fig">2</xref>.<fig position="float" id="F2" orientation="portrait"><label>Figure 2.</label><caption><p>Workflow illustrating radiomics analysis.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="js9-111-6232-g002.jpg"/></fig>
</p></sec><sec><title>Image preprocessing</title><p>To minimize the impact of images from different imaging devices on the generalizability of radiomics models, this study conducted a two-step post-processing approach. First, the N4 bias field correction method based on the SimpleITK toolkit in Python 3.7.1 was initially employed to eliminate the influence of uneven signal intensity caused by inhomogeneous magnetic field variations across images. Subsequently, the zoom toolkit was utilized to resample these images from three sequences, adjusting the voxel size to 1 mm&#160;&#215;1 mm&#160;&#215;1 mm. Trilinear interpolation was adopted for image resampling, while the nearest neighbor interpolation technique was applied to the masks. Finally, the T1WI and T2WI images were registered onto the T1C images, thus providing an accurate and standardized image dataset for subsequent image analysis.</p></sec><sec><title>Habitat imaging and radiomics feature extraction</title><p>Intratumoral and peritumoral habitat regions were primarily defined through the utilization of the sklearn.cluster. Kmeans toolkit in Python 3.7.1. Compared to the Gaussian Mixture Model and the OTSU Method, the K-means clustering method boasts several advantages, including high computational efficiency, robust adaptability to data distribution, and enhanced interpretability of results<sup>[<xref rid="R36" ref-type="bibr">36</xref>-<xref rid="R38" ref-type="bibr">38</xref>]</sup>. In this study, HI was conducted on T1WI, T2WI, and T1C images. Each voxel within the intratumoral and peritumoral areas encompassed paired data of these three sequences. The combination of these paired data from all voxels across the entire patient cohort generated a data array with a dimension of N &#215;&#160;3, where N denotes the number of image voxels, and 3 corresponds to the parameters of the three sequence images. Thereafter, a K-means clustering method was constructed based on the aforementioned dataset to allocate each voxel to a specific cluster or habitat. K-means clustering is an iterative approach that partitions n data points into k clusters by assigning each data point to the cluster with the closest mean. This method initiates with a random assignment, recalculates the means, and iterates until the cluster assignments stabilize or a predefined limit is attained. The Sum of Squared Errors (SSE) was employed to assess clustering quality. SSE serves as a crucial evaluation metric in the K-means clustering algorithm, estimating the sum of the squared distances from each data point to the center of its affiliated cluster. The elbow method was utilized to determine the optimal value of k by identifying the inflection point of the SSE, where the rate of decline abruptly slows. In this study, the inflection points for both the intratumoral and peritumoral regions were 5, thus subdividing the sub-regions into h1, h2, h3, h4, and h5. Meanwhile, we also performed K-means clustering analysis on data from both centers so as to ensure the robustness of the K-means clustering algorithm across different cohorts, and found that the optimal number of clusters was consistently 5 for both datasets (Supplemental Digital Content, Figure S1, available at: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://links.lww.com/JS9/E434" ext-link-type="uri">http://links.lww.com/JS9/E434</ext-link>).</p><p>In order to avoid overfitting as much as possible, 107 low-dimensional radiomics features were extracted from each sub-region using the Pyradiomics package of Python (version 3.7.1), including the shape (n&#160;=&#160;14), first order (n&#160;=&#160;18), gray-level co-occurrence matrix (GLCM, n =&#160;24), gray-level run-length matrix (GLRLM, n =&#160;16), gray-level size zone matrix (GLSZM, n =&#160;16), neighborhood gray-tone difference matrix (NGTDM, n =&#160;5), and gray-level dependence matrix (GLDM, n =&#160;14). Finally, 1070 radiomics features were acquired from each sequence for subsequent model construction and analysis.</p></sec><sec><title>Feature selection and model construction</title><p>This study employed a two-stage feature selection pipeline to optimize model performance. First, radiomics features were standardized using the Z-score approach to ensure that the mean value of the features was 0 and the variance was 1.Dimensionality reduction was then performed using Pearson correlation coefficient. When the correlation coefficient |R| between two features exceeded 0.95, one of the features was eliminated. The remaining features underwent further refinement, which was performed using the 10-fold cross-validated LassoCV method to identify the most relevant ones for the model.</p><p>In this study, five machine learning algorithms, including Logistic Regression (LR), Support Vector Machine (SVM), K-Nearest Neighbors (KNN), Decision Tree (DT), and Random Forest (RF), were used to construct predictive models. To evaluate the prediction models&#8217; validity, five-fold cross-validation was also performed on the dataset. In comparison to the bootstrapping method, five-fold cross-validation is less susceptible to the randomness of data partitioning, yields relatively consistent evaluation outcomes, and thus effectively mitigates the risk of overfitting[<xref rid="R39" ref-type="bibr">39</xref>]. Meanwhile, model performance was evaluated using average area under the curve (AUC)value of the receiver operating characteristic (ROC) curve across folds. This approach minimized overfitting and ensured robust evaluation.</p><p>This study developed five pCR prediction models: Intratumoral HI models, Intratumoral Fusion model, Peritumoral HI models, Peritumoral Fusion model, and the decision model. The Intratumoral and Peritumoral HI models were constructed using HI features from different sequences, while their respective Fusion models integrated HI features from three sequences. The decision model incorporated clinical characteristics along with both intratumoral and peritumoral HI features.</p></sec><sec><title>Biological interpretability analysis</title><p>In order to evaluate the contribution of the finally screened features to the predictive model, SHapley Additive exPlanations (SHAP) analysis was performed to evaluate the interpretability of the linear model, revealing the complex mechanism of machine learning model prediction. SHAP visualizes the contribution of each feature to the model prediction by assigning an importance value to each feature in each prediction, indicating how it increases or decreases the probability of a specific outcome. The SHAP analysis was carried out using the explainers. Linear function of the SHAP toolkit in Python (version 3.7.1).</p><p>To further enhance model interpretability, the association between the important radiomic features after SHAP screening in the decision model and PD-L1CPS was comprehensively explored. Given the correlation between PD-L1CPSand treatment effectiveness in head and neck carcinoma, a threshold of CPS greater than or equal to 15 was applied for subsequent analysis. Meanwhile, CD45+&#160;white blood cells, CD3+&#160;T cells, and CD19+&#160;B cells in baseline biopsy tissue were quantified using multiplex immunofluorescence assays in pCR patients (n&#160;=&#160;3) and non-pCR patients (n&#160;=&#160;3) from Institution B to identify biomarkers related to pCR. The cells were separately quantified in the tumor and stroma. By systematically analyzing the correlation between important radiomic features in the final model and the aforementioned biomarkers, this study aimed to expand our understanding of the potential mechanism underlying disease occurrence and development, providing a valuable theoretical reference for clinical diagnosis and treatment.</p></sec></sec><sec><title>Statistical analysis</title><p>Statistical analyses were performed using Python version 3.7.1. Regarding clinical baseline characteristics, continuous variables were expressed as mean&#160;&#177;&#160;standard deviation and compared using the independent-samples t-test or the Mann&#8211;Whitney U test. Ordinal variables were presented as median (first quartile, third quartile) and compared using the chi-square test. It is important to note that a few minimal clinical features, such as the baseline hematological index, were missing. These missing values were primarily imputed using the median value. For radiomics features with missing data, the machine learning algorithm KNNImputer was employed for imputation. In the context of pathological validation, the t-test was used to evaluate correlations between the screened radiomics features and PD-L1CPS, with <italic toggle="yes">P</italic> &lt; 0.05 regarded as statistically significant. Pearson correlation analysis was conducted to evaluate the association between peritumoral subregion features and screened biomarkers, with |R|&#160;&gt;&#160;0.75 indicating a strong correlation. To evaluate the discriminatory ability of the models, ROC curves, calibration curves, and confusion matrix were utilized, and model performance was evaluated by calculating the AUC, accuracy, recall, precision, and F1 score to comprehensively and objectively evaluate the reliability and validity of this study.</p></sec><sec sec-type="results"><title>Results</title><sec sec-type="subjects"><title>Patient characteristics</title><p>The demographic characteristics of the study cohort are listed in Table <xref rid="T1" ref-type="table">1</xref>. Among the 212 patients included in the analysis, 56 individuals (26.4 %) achieved pCR. Significant differences were observed between the pCR and non-pCR groups in pre-N status (<italic toggle="yes">P</italic> =&#160;0.042), number of immunotherapy cycles (<italic toggle="yes">P</italic> =&#160;0.006), post-T status (<italic toggle="yes">P</italic> =&#160;0.006), PLT (<italic toggle="yes">P</italic> =&#160;0.019), and MON (<italic toggle="yes">P</italic> =&#160;0.046).<table-wrap position="float" id="T1" orientation="portrait"><label>Table 1</label><caption><p>Patient characteristics</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1">pCR</th><th align="center" rowspan="1" colspan="1">Non-pCR</th><th align="center" rowspan="1" colspan="1"><italic toggle="yes">P</italic></th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Sex</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0.096</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Female</td><td align="center" rowspan="1" colspan="1">6(10.7%)</td><td align="center" rowspan="1" colspan="1">7(4.5%)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Male</td><td align="center" rowspan="1" colspan="1">50(89.3%)</td><td align="center" rowspan="1" colspan="1">149(95.5%)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Smoking history</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0.579</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;NO</td><td align="center" rowspan="1" colspan="1">14(25%)</td><td align="center" rowspan="1" colspan="1">29(18.6%)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Yes</td><td align="center" rowspan="1" colspan="1">27(48.2%)</td><td align="center" rowspan="1" colspan="1">84(53.8%)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Quit</td><td align="center" rowspan="1" colspan="1">15(26.8%)</td><td align="center" rowspan="1" colspan="1">43(27.6%)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Drinking history</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0.139</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;No</td><td align="center" rowspan="1" colspan="1">32(57.1%)</td><td align="center" rowspan="1" colspan="1">66(42.3%)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Yes</td><td align="center" rowspan="1" colspan="1">16(28.6%)</td><td align="center" rowspan="1" colspan="1">54(34.6%)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Quit</td><td align="center" rowspan="1" colspan="1">8(14.3%)</td><td align="center" rowspan="1" colspan="1">36(23.1%)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">preT</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0.911</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;T1</td><td align="center" rowspan="1" colspan="1">1(1.8%)</td><td align="center" rowspan="1" colspan="1">1(0.6%)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;T2</td><td align="center" rowspan="1" colspan="1">6(10.7%)</td><td align="center" rowspan="1" colspan="1">13(8.3%)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;T3</td><td align="center" rowspan="1" colspan="1">19(33.9%)</td><td align="center" rowspan="1" colspan="1">57(36.5%)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;T4a</td><td align="center" rowspan="1" colspan="1">20(35.7%)</td><td align="center" rowspan="1" colspan="1">59(37.8%)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;T4b</td><td align="center" rowspan="1" colspan="1">10(17.9%)</td><td align="center" rowspan="1" colspan="1">26(16.7%)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">preN</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0.042<xref rid="tbl1-fn1" ref-type="table-fn">a</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;N0</td><td align="center" rowspan="1" colspan="1">24(42.9%)</td><td align="center" rowspan="1" colspan="1">54(34.6%)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;N1</td><td align="center" rowspan="1" colspan="1">8(14.3%)</td><td align="center" rowspan="1" colspan="1">24(15.4%)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;N2a</td><td align="center" rowspan="1" colspan="1">1(1.8%)</td><td align="center" rowspan="1" colspan="1">3(1.9%)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;N2b</td><td align="center" rowspan="1" colspan="1">5(8.9%)</td><td align="center" rowspan="1" colspan="1">43(27.6%)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;N2c</td><td align="center" rowspan="1" colspan="1">4(7.1%)</td><td align="center" rowspan="1" colspan="1">13(8.3%)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;N3a</td><td align="center" rowspan="1" colspan="1">0(0%)</td><td align="center" rowspan="1" colspan="1">0(0%)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;N3b</td><td align="center" rowspan="1" colspan="1">14(25%)</td><td align="center" rowspan="1" colspan="1">19(12.2%)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">preStage</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0.231</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;II</td><td align="center" rowspan="1" colspan="1">1(1.8%)</td><td align="center" rowspan="1" colspan="1">6(3.8%)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;III</td><td align="center" rowspan="1" colspan="1">16(28.6%)</td><td align="center" rowspan="1" colspan="1">37(23.7%)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;IVa</td><td align="center" rowspan="1" colspan="1">19(33.9%)</td><td align="center" rowspan="1" colspan="1">75(48.1%)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;IVb</td><td align="center" rowspan="1" colspan="1">20(35.7%)</td><td align="center" rowspan="1" colspan="1">38(24.3%)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Number of induction cycles</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0.006<xref rid="tbl1-fn1" ref-type="table-fn">a</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;1</td><td align="center" rowspan="1" colspan="1">3(5.4%)</td><td align="center" rowspan="1" colspan="1">2(1.3%)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;2</td><td align="center" rowspan="1" colspan="1">26(46.4%)</td><td align="center" rowspan="1" colspan="1">85(54.5%)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;3</td><td align="center" rowspan="1" colspan="1">23(41.1%)</td><td align="center" rowspan="1" colspan="1">58(37.2%)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;4</td><td align="center" rowspan="1" colspan="1">0(0%)</td><td align="center" rowspan="1" colspan="1">10(6.4%)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;5</td><td align="center" rowspan="1" colspan="1">4(7.1%)</td><td align="center" rowspan="1" colspan="1">1(0.6%)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">postT</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0.006<xref rid="tbl1-fn1" ref-type="table-fn">a</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;T0</td><td align="center" rowspan="1" colspan="1">8(14.3%)</td><td align="center" rowspan="1" colspan="1">23(14.7%)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;T1</td><td align="center" rowspan="1" colspan="1">4(7.1%)</td><td align="center" rowspan="1" colspan="1">19(12.2%)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;T2</td><td align="center" rowspan="1" colspan="1">6(10.7%)</td><td align="center" rowspan="1" colspan="1">38(24.4%)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;T3</td><td align="center" rowspan="1" colspan="1">28(50%)</td><td align="center" rowspan="1" colspan="1">35(22.4%)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;T4a</td><td align="center" rowspan="1" colspan="1">6(10.7%)</td><td align="center" rowspan="1" colspan="1">23(14.7%)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;T4b</td><td align="center" rowspan="1" colspan="1">4(7.1%)</td><td align="center" rowspan="1" colspan="1">18(11.5%)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">postN</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0.702</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;N0</td><td align="center" rowspan="1" colspan="1">33(58.9%)</td><td align="center" rowspan="1" colspan="1">77(49.4%)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;N1</td><td align="center" rowspan="1" colspan="1">8(14.3%)</td><td align="center" rowspan="1" colspan="1">25(16%)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;N2a</td><td align="center" rowspan="1" colspan="1">1(1.8%)</td><td align="center" rowspan="1" colspan="1">5(3.2%)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;N2b</td><td align="center" rowspan="1" colspan="1">7(12.5%)</td><td align="center" rowspan="1" colspan="1">32(20.5%)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;N2c</td><td align="center" rowspan="1" colspan="1">2(3.6%)</td><td align="center" rowspan="1" colspan="1">7(4.5%)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;N3a</td><td align="center" rowspan="1" colspan="1">0(0%)</td><td align="center" rowspan="1" colspan="1">0(0%)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;N3b</td><td align="center" rowspan="1" colspan="1">5(8.9%)</td><td align="center" rowspan="1" colspan="1">10(6.4%)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">postStage</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0.881</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;0</td><td align="center" rowspan="1" colspan="1">16(28.6%)</td><td align="center" rowspan="1" colspan="1">38(24.4%)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;I</td><td align="center" rowspan="1" colspan="1">7(12.5%)</td><td align="center" rowspan="1" colspan="1">23(14.7%)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;II</td><td align="center" rowspan="1" colspan="1">5(8.9%)</td><td align="center" rowspan="1" colspan="1">14(9.0%)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;III</td><td align="center" rowspan="1" colspan="1">13(23.2%)</td><td align="center" rowspan="1" colspan="1">31(19.9%)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;IVa</td><td align="center" rowspan="1" colspan="1">12(21.4%)</td><td align="center" rowspan="1" colspan="1">34(21.8%)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;IVb</td><td align="center" rowspan="1" colspan="1">3(5.4%)</td><td align="center" rowspan="1" colspan="1">16(10.3%)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">BMI</td><td align="center" rowspan="1" colspan="1">23.7&#160;&#177;&#160;4.4</td><td align="center" rowspan="1" colspan="1">24.1&#160;&#177;&#160;4.1</td><td align="center" rowspan="1" colspan="1">0.919</td></tr><tr><td align="left" rowspan="1" colspan="1">PLT</td><td align="center" rowspan="1" colspan="1">242.0&#160;&#177;&#160;78.5</td><td align="center" rowspan="1" colspan="1">244.2&#160;&#177;&#160;60.3</td><td align="center" rowspan="1" colspan="1">0.019<xref rid="tbl1-fn1" ref-type="table-fn">a</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">AGE</td><td align="center" rowspan="1" colspan="1">54(46.2,59.0)</td><td align="center" rowspan="1" colspan="1">50(44.0,56.3)</td><td align="center" rowspan="1" colspan="1">0.146</td></tr><tr><td align="left" rowspan="1" colspan="1">WBC</td><td align="center" rowspan="1" colspan="1">6.9(5.8,8.4)</td><td align="center" rowspan="1" colspan="1">7.1 (6.0,8.2)</td><td align="center" rowspan="1" colspan="1">0.620</td></tr><tr><td align="left" rowspan="1" colspan="1">NEU</td><td align="center" rowspan="1" colspan="1">4.17(3.2,5.4)</td><td align="center" rowspan="1" colspan="1">4.34(3.5,5.2)</td><td align="center" rowspan="1" colspan="1">0.549</td></tr><tr><td align="left" rowspan="1" colspan="1">Monocyte value</td><td align="center" rowspan="1" colspan="1">0.49(0.4,0.6)</td><td align="center" rowspan="1" colspan="1">0.6(0.4,0.7)</td><td align="center" rowspan="1" colspan="1">0.135</td></tr><tr><td align="left" rowspan="1" colspan="1">MON</td><td align="center" rowspan="1" colspan="1">6.7(5.6,7.5)</td><td align="center" rowspan="1" colspan="1">7.2(5.9,8.4)</td><td align="center" rowspan="1" colspan="1">0.046<xref rid="tbl1-fn1" ref-type="table-fn">a</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">HGB</td><td align="center" rowspan="1" colspan="1">150(137.8,160.3)</td><td align="center" rowspan="1" colspan="1">150(140.0,158.0)</td><td align="center" rowspan="1" colspan="1">0.906</td></tr><tr><td align="left" rowspan="1" colspan="1">PDW</td><td align="center" rowspan="1" colspan="1">11.6(10.8,13.3)</td><td align="center" rowspan="1" colspan="1">11.6(10.4,12.8)</td><td align="center" rowspan="1" colspan="1">0.577</td></tr><tr><td align="left" rowspan="1" colspan="1">ALT</td><td align="center" rowspan="1" colspan="1">23(16.9,33.0)</td><td align="center" rowspan="1" colspan="1">24.0(17.1,39.5)</td><td align="center" rowspan="1" colspan="1">0.458</td></tr><tr><td align="left" rowspan="1" colspan="1">AST</td><td align="center" rowspan="1" colspan="1">20.3(16.3,28.1)</td><td align="center" rowspan="1" colspan="1">21.45(17.4,29.0)</td><td align="center" rowspan="1" colspan="1">0.369</td></tr><tr><td align="left" rowspan="1" colspan="1">ALB</td><td align="center" rowspan="1" colspan="1">43.3(41.0,45.0)</td><td align="center" rowspan="1" colspan="1">43.2(41.1,45.5)</td><td align="center" rowspan="1" colspan="1">0.802</td></tr><tr><td align="left" rowspan="1" colspan="1">GLO</td><td align="center" rowspan="1" colspan="1">28.2 (25.7,32.4)</td><td align="center" rowspan="1" colspan="1">27.5(25.0,30.8)</td><td align="center" rowspan="1" colspan="1">0.214</td></tr><tr><td align="left" rowspan="1" colspan="1">AGR</td><td align="center" rowspan="1" colspan="1">1.5 (1.3,1.7)</td><td align="center" rowspan="1" colspan="1">1.6 (1.4,1.7)</td><td align="center" rowspan="1" colspan="1">0.250</td></tr></tbody></table><table-wrap-foot><fn id="tbl1-fn1"><label><sup>a</sup></label><p>Statistically significant. AGR: albumin-globulin ratio; ALB: albumin; ALT: alanine aminotransferase; AST: aspartate transaminase; BMI: body mass index; GLO: globulin; HGB: hemoglobin; MON: monocyte; NEU: neutropenia; PDW: platelet distribution width; PLT: platelet; WBC: white blood cell count.</p></fn></table-wrap-foot></table-wrap>
</p></sec><sec><title>The comparison between different models</title><p>Given that LR algorithm consistently outperformed other machine learning algorithms across different models (Supplemental Digital Content, Table S2, available at: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://links.lww.com/JS9/E436" ext-link-type="uri">http://links.lww.com/JS9/E436</ext-link>; Table S3, available at: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://links.lww.com/JS9/E437" ext-link-type="uri">http://links.lww.com/JS9/E437</ext-link>; Table S4, available at: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://links.lww.com/JS9/E438" ext-link-type="uri">http://links.lww.com/JS9/E438</ext-link>), this study primarily presents the results derived from LR. Figure <xref rid="F3" ref-type="fig">3</xref>A and Table <xref rid="T2" ref-type="table">2</xref> summarize the performance of the HI and Fusion models, with all LR algorithms achieving satisfactory results. The peritumoral HI and Fusion models were minimally higher than those of the intratumoral models. Specifically, peritumoral HI models demonstrated average AUC ranges of 0.748&#8211;0.788 (training) and 0.734&#8211;0.790 (testing), while peritumoral Fusion model achieved 0.869/0.822. In comparison, intratumoral HI models showed AUCs of 0.738&#8211;0.793 (training) and 0.729&#8211;0.774 (testing), and intratumoral Fusion model scored 0.817/0.789. Complementary performance metrics, including precision, recall, and F1 scores, also further supported these trends (Table <xref rid="T2" ref-type="table">2</xref>). Specifically, peritumoral HI models demonstrated superior discriminative ability with precision ranging from 0.777&#8211;0.797 (training) and 0.759&#8211;0.782 (testing), recall values between 0.944&#8211;0.956 (training) and 0.901&#8211;0.928 (testing), and F1 scores of 0.855&#8211;0.869 (training) and 0.828&#8211;0.837 (testing). Intratumoral HI models achieved comparable results, with precision of 0.767&#8211;0.802 (training) and 0.752&#8211;0.770 (testing), recall of 0.930&#8211;0.966 (training) and 0.900&#8211;0.968 (testing), and F1 scores of 0.848&#8211;0.861 (training) and 0.819&#8211;0.852 (testing). Fusion models exhibited consistent improvements across these metrics. Peritumoral Fusion model attained precision/recall/F1 scores of 0.831/0.930/0.877 (training) and 0.783/0.902/0.827 (testing), while intratumoral Fusion model achieved 0.816/0.942/0.874 (training) and 0.803/0.926/0.789 (testing).<fig position="float" id="F3" orientation="portrait"><label>Figure 3.</label><caption><p>Comparison of different models and feature details in the decision model. (A) Box-and-whisker plots of AUC values for all models. (B) ROC curves in the training and testing cohorts for the decision model. AUC values are expressed as the mean and standard deviation across the five training and validation sets from the 5-fold cross-validation. The confusion matrices with heatmaps for the five validation sets of the decision model. The numbers in each colored box represent the percentage of instances between the true and the predicted classes obtained by the decision models. ROC, receiver-operating characteristic; AUC, area under the curve. (C) Details of clinical, peritumoral habitat features (PHF<sub>S</sub>) and intratumoral habitat features (IHF<sub>S</sub>) included in the decision model. T1, T1-weighted imaging; T1C, contrast-enhanced T1-weighted imaging with fat suppression; T2, axial T2-weighted imaging with fat suppression; Intra, intratumoral; Peri, peritumoral; P, peritumoral; I, intratumoral; h, habitat; GLCM, gray-level co-occurrence matrix; GLRLM, gray-level run-length matrix; GLSZM, gray-level size zone matrix; NGTDM, neighborhood gray-tone difference matrix.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="js9-111-6232-g003.jpg"/></fig>
<table-wrap position="float" id="T2" orientation="portrait"><label>Table 2</label><caption><p>Performance of the intratumoral and peritumoral habitat imaging (HI) models across different sequences with corresponding fusion models</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1">AUC</th><th align="center" rowspan="1" colspan="1">Accuracy</th><th align="center" rowspan="1" colspan="1">Recall</th><th align="center" rowspan="1" colspan="1">Precision</th><th align="center" rowspan="1" colspan="1">F1-score</th><th align="center" rowspan="1" colspan="1">PPV</th><th align="center" rowspan="1" colspan="1">NPV</th></tr></thead><tbody><tr><td align="left" colspan="8" rowspan="1">T1-Intra</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Train</td><td align="center" rowspan="1" colspan="1">0.750</td><td align="center" rowspan="1" colspan="1">0.765</td><td align="center" rowspan="1" colspan="1">0.966</td><td align="center" rowspan="1" colspan="1">0.772</td><td align="center" rowspan="1" colspan="1">0.858</td><td align="center" rowspan="1" colspan="1">0.772</td><td align="center" rowspan="1" colspan="1">0.684</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Test</td><td align="center" rowspan="1" colspan="1">0.748</td><td align="center" rowspan="1" colspan="1">0.759</td><td align="center" rowspan="1" colspan="1">0.968</td><td align="center" rowspan="1" colspan="1">0.770</td><td align="center" rowspan="1" colspan="1">0.852</td><td align="center" rowspan="1" colspan="1">0.770</td><td align="center" rowspan="1" colspan="1">0.640</td></tr><tr><td align="left" colspan="8" rowspan="1">T1C-Intra</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Train</td><td align="center" rowspan="1" colspan="1">0.793</td><td align="center" rowspan="1" colspan="1">0.781</td><td align="center" rowspan="1" colspan="1">0.930</td><td align="center" rowspan="1" colspan="1">0.802</td><td align="center" rowspan="1" colspan="1">0.861</td><td align="center" rowspan="1" colspan="1">0.802</td><td align="center" rowspan="1" colspan="1">0.656</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Test</td><td align="center" rowspan="1" colspan="1">0.774</td><td align="center" rowspan="1" colspan="1">0.722</td><td align="center" rowspan="1" colspan="1">0.900</td><td align="center" rowspan="1" colspan="1">0.769</td><td align="center" rowspan="1" colspan="1">0.824</td><td align="center" rowspan="1" colspan="1">0.769</td><td align="center" rowspan="1" colspan="1">0.465</td></tr><tr><td align="left" colspan="8" rowspan="1">T2-Intra</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Train</td><td align="center" rowspan="1" colspan="1">0.738</td><td align="center" rowspan="1" colspan="1">0.738</td><td align="center" rowspan="1" colspan="1">0.948</td><td align="center" rowspan="1" colspan="1">0.767</td><td align="center" rowspan="1" colspan="1">0.848</td><td align="center" rowspan="1" colspan="1">0.767</td><td align="center" rowspan="1" colspan="1">0.585</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Test</td><td align="center" rowspan="1" colspan="1">0.729</td><td align="center" rowspan="1" colspan="1">0.708</td><td align="center" rowspan="1" colspan="1">0.914</td><td align="center" rowspan="1" colspan="1">0.752</td><td align="center" rowspan="1" colspan="1">0.819</td><td align="center" rowspan="1" colspan="1">0.752</td><td align="center" rowspan="1" colspan="1">0.404</td></tr><tr><td align="left" colspan="8" rowspan="1">Intra-Fusion</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Train</td><td align="center" rowspan="1" colspan="1">0.817</td><td align="center" rowspan="1" colspan="1">0.801</td><td align="center" rowspan="1" colspan="1">0.942</td><td align="center" rowspan="1" colspan="1">0.816</td><td align="center" rowspan="1" colspan="1">0.874</td><td align="center" rowspan="1" colspan="1">0.816</td><td align="center" rowspan="1" colspan="1">0.715</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Test</td><td align="center" rowspan="1" colspan="1">0.789</td><td align="center" rowspan="1" colspan="1">0.774</td><td align="center" rowspan="1" colspan="1">0.926</td><td align="center" rowspan="1" colspan="1">0.803</td><td align="center" rowspan="1" colspan="1">0.789</td><td align="center" rowspan="1" colspan="1">0.803</td><td align="center" rowspan="1" colspan="1">0.663</td></tr><tr><td align="left" colspan="8" rowspan="1">T1-Peri</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Train</td><td align="center" rowspan="1" colspan="1">0.781</td><td align="center" rowspan="1" colspan="1">0.789</td><td align="center" rowspan="1" colspan="1">0.956</td><td align="center" rowspan="1" colspan="1">0.797</td><td align="center" rowspan="1" colspan="1">0.869</td><td align="center" rowspan="1" colspan="1">0.797</td><td align="center" rowspan="1" colspan="1">0.733</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Test</td><td align="center" rowspan="1" colspan="1">0.771</td><td align="center" rowspan="1" colspan="1">0.741</td><td align="center" rowspan="1" colspan="1">0.926</td><td align="center" rowspan="1" colspan="1">0.773</td><td align="center" rowspan="1" colspan="1">0.837</td><td align="center" rowspan="1" colspan="1">0.773</td><td align="center" rowspan="1" colspan="1">0.551</td></tr><tr><td align="left" colspan="8" rowspan="1">T1C-Peri</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Train</td><td align="center" rowspan="1" colspan="1">0.788</td><td align="center" rowspan="1" colspan="1">0.777</td><td align="center" rowspan="1" colspan="1">0.944</td><td align="center" rowspan="1" colspan="1">0.791</td><td align="center" rowspan="1" colspan="1">0.861</td><td align="center" rowspan="1" colspan="1">0.791</td><td align="center" rowspan="1" colspan="1">0.687</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Test</td><td align="center" rowspan="1" colspan="1">0.790</td><td align="center" rowspan="1" colspan="1">0.736</td><td align="center" rowspan="1" colspan="1">0.901</td><td align="center" rowspan="1" colspan="1">0.782</td><td align="center" rowspan="1" colspan="1">0.828</td><td align="center" rowspan="1" colspan="1">0.782</td><td align="center" rowspan="1" colspan="1">0.550</td></tr><tr><td align="left" colspan="8" rowspan="1">T2-Peri</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Train</td><td align="center" rowspan="1" colspan="1">0.748</td><td align="center" rowspan="1" colspan="1">0.763</td><td align="center" rowspan="1" colspan="1">0.950</td><td align="center" rowspan="1" colspan="1">0.777</td><td align="center" rowspan="1" colspan="1">0.855</td><td align="center" rowspan="1" colspan="1">0.777</td><td align="center" rowspan="1" colspan="1">0.642</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Test</td><td align="center" rowspan="1" colspan="1">0.734</td><td align="center" rowspan="1" colspan="1">0.731</td><td align="center" rowspan="1" colspan="1">0.928</td><td align="center" rowspan="1" colspan="1">0.759</td><td align="center" rowspan="1" colspan="1">0.831</td><td align="center" rowspan="1" colspan="1">0.759</td><td align="center" rowspan="1" colspan="1">0.490</td></tr><tr><td align="left" colspan="8" rowspan="1">Peri-Fusion</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Train</td><td align="center" rowspan="1" colspan="1">0.869</td><td align="center" rowspan="1" colspan="1">0.810</td><td align="center" rowspan="1" colspan="1">0.930</td><td align="center" rowspan="1" colspan="1">0.831</td><td align="center" rowspan="1" colspan="1">0.877</td><td align="center" rowspan="1" colspan="1">0.831</td><td align="center" rowspan="1" colspan="1">0.718</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Test</td><td align="center" rowspan="1" colspan="1">0.822</td><td align="center" rowspan="1" colspan="1">0.727</td><td align="center" rowspan="1" colspan="1">0.902</td><td align="center" rowspan="1" colspan="1">0.783</td><td align="center" rowspan="1" colspan="1">0.827</td><td align="center" rowspan="1" colspan="1">0.783</td><td align="center" rowspan="1" colspan="1">0.493</td></tr></tbody></table><table-wrap-foot><fn fn-type="other"><p>AUC: area under curve; Intra: intratumoral; NPV: negative predictive value; Peri: peritumoral; PPV: positive predictive value; T1: T1-weighted imaging; T1C: contrast-enhanced T1-weighted imaging with fat suppression; T2: axial T2-weighted imaging with fat suppression.</p></fn></table-wrap-foot></table-wrap>
</p><p>An optimal decision model was constructed based on peritumoral habitat features (PHF<sub>S</sub>), intratumoral habitat features (IHF<sub>S</sub>), and clinical features. The average AUC values of the decision model in the training and testing sets were 0.913 and 0.843, respectively. In terms of precision, recall, and F1 score, the decision model achieved values of 0.884, 0.955, and 0.918 in the training set, whereas in the testing set these values were 0.835, 0.897, and 0.840. Details are presented in Table <xref rid="T3" ref-type="table">3</xref> and Fig. <xref rid="F3" ref-type="fig">3</xref>B. Figure <xref rid="F3" ref-type="fig">3</xref>C displays the selected features and their corresponding coefficients in this model, consisting of 18 PHF<sub>S</sub>, 16 IHF<sub>S</sub>, and 3 clinical features (number of induction cycles, postT, AGR). Meanwhile, Fig. <xref rid="F3" ref-type="fig">3</xref>B delineates the ROC curve of the decision model and the confusion matrix in the 5-fold cross-validation set. The calibration curves for this model in the training and testing sets are presented in Supplemental Digital Content, Figure S2 (available at: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://links.lww.com/JS9/E434" ext-link-type="uri">http://links.lww.com/JS9/E434</ext-link>).<table-wrap position="float" id="T3" orientation="portrait"><label>Table 3</label><caption><p>Performance of the decision model with five-fold cross-validation</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">Fold</th><th align="center" rowspan="1" colspan="1">Cohort</th><th align="center" rowspan="1" colspan="1">AUC</th><th align="center" rowspan="1" colspan="1">Accuracy</th><th align="center" rowspan="1" colspan="1">Recall</th><th align="center" rowspan="1" colspan="1">Precision</th><th align="center" rowspan="1" colspan="1">F1-score</th><th align="center" rowspan="1" colspan="1">PPV</th><th align="center" rowspan="1" colspan="1">NPV</th></tr></thead><tbody><tr><td align="left" rowspan="2" colspan="1">Fold 1</td><td align="left" rowspan="1" colspan="1">Train</td><td align="center" rowspan="1" colspan="1">0.938</td><td align="center" rowspan="1" colspan="1">0.888</td><td align="center" rowspan="1" colspan="1">0.96</td><td align="center" rowspan="1" colspan="1">0.896</td><td align="center" rowspan="1" colspan="1">0.927</td><td align="center" rowspan="1" colspan="1">0.896</td><td align="center" rowspan="1" colspan="1">0.853</td></tr><tr><td align="left" rowspan="1" colspan="1">Test</td><td align="center" rowspan="1" colspan="1">0.787</td><td align="center" rowspan="1" colspan="1">0.767</td><td align="center" rowspan="1" colspan="1">0.967</td><td align="center" rowspan="1" colspan="1">0.763</td><td align="center" rowspan="1" colspan="1">0.853</td><td align="center" rowspan="1" colspan="1">0.763</td><td align="center" rowspan="1" colspan="1">0.800</td></tr><tr><td align="left" rowspan="2" colspan="1">Fold 2</td><td align="left" rowspan="1" colspan="1">Train</td><td align="center" rowspan="1" colspan="1">0.908</td><td align="center" rowspan="1" colspan="1">0.852</td><td align="center" rowspan="1" colspan="1">0.952</td><td align="center" rowspan="1" colspan="1">0.861</td><td align="center" rowspan="1" colspan="1">0.904</td><td align="center" rowspan="1" colspan="1">0.861</td><td align="center" rowspan="1" colspan="1">0.812</td></tr><tr><td align="left" rowspan="1" colspan="1">Test</td><td align="center" rowspan="1" colspan="1">0.855</td><td align="center" rowspan="1" colspan="1">0.791</td><td align="center" rowspan="1" colspan="1">0.875</td><td align="center" rowspan="1" colspan="1">0.848</td><td align="center" rowspan="1" colspan="1">0.812</td><td align="center" rowspan="1" colspan="1">0.848</td><td align="center" rowspan="1" colspan="1">0.600</td></tr><tr><td align="left" rowspan="2" colspan="1">Fold 3</td><td align="left" rowspan="1" colspan="1">Train</td><td align="center" rowspan="1" colspan="1">0.913</td><td align="center" rowspan="1" colspan="1">0.888</td><td align="center" rowspan="1" colspan="1">0.969</td><td align="center" rowspan="1" colspan="1">0.894</td><td align="center" rowspan="1" colspan="1">0.93</td><td align="center" rowspan="1" colspan="1">0.894</td><td align="center" rowspan="1" colspan="1">0.857</td></tr><tr><td align="left" rowspan="1" colspan="1">Test</td><td align="center" rowspan="1" colspan="1">0.816</td><td align="center" rowspan="1" colspan="1">0.810</td><td align="center" rowspan="1" colspan="1">0.96</td><td align="center" rowspan="1" colspan="1">0.774</td><td align="center" rowspan="1" colspan="1">0.857</td><td align="center" rowspan="1" colspan="1">0.774</td><td align="center" rowspan="1" colspan="1">0.909</td></tr><tr><td align="left" rowspan="2" colspan="1">Fold 4</td><td align="left" rowspan="1" colspan="1">Train</td><td align="center" rowspan="1" colspan="1">0.912</td><td align="center" rowspan="1" colspan="1">0.888</td><td align="center" rowspan="1" colspan="1">0.96</td><td align="center" rowspan="1" colspan="1">0.895</td><td align="center" rowspan="1" colspan="1">0.926</td><td align="center" rowspan="1" colspan="1">0.895</td><td align="center" rowspan="1" colspan="1">0.865</td></tr><tr><td align="left" rowspan="1" colspan="1">Test</td><td align="center" rowspan="1" colspan="1">0.816</td><td align="center" rowspan="1" colspan="1">0.81</td><td align="center" rowspan="1" colspan="1">0.96</td><td align="center" rowspan="1" colspan="1">0.774</td><td align="center" rowspan="1" colspan="1">0.857</td><td align="center" rowspan="1" colspan="1">0.774</td><td align="center" rowspan="1" colspan="1">0.909</td></tr><tr><td align="left" rowspan="2" colspan="1">Fold 5</td><td align="left" rowspan="1" colspan="1">Train</td><td align="center" rowspan="1" colspan="1">0.905</td><td align="center" rowspan="1" colspan="1">0.859</td><td align="center" rowspan="1" colspan="1">0.933</td><td align="center" rowspan="1" colspan="1">0.874</td><td align="center" rowspan="1" colspan="1">0.902</td><td align="center" rowspan="1" colspan="1">0.874</td><td align="center" rowspan="1" colspan="1">0.814</td></tr><tr><td align="left" rowspan="1" colspan="1">Test</td><td align="center" rowspan="1" colspan="1">0.941</td><td align="center" rowspan="1" colspan="1">0.833</td><td align="center" rowspan="1" colspan="1">0.838</td><td align="center" rowspan="1" colspan="1">0.969</td><td align="center" rowspan="1" colspan="1">0.814</td><td align="center" rowspan="1" colspan="1">0.969</td><td align="center" rowspan="1" colspan="1">0.400</td></tr><tr><td align="left" rowspan="2" colspan="1">Mean</td><td align="left" rowspan="1" colspan="1">Train</td><td align="center" rowspan="1" colspan="1">0.913</td><td align="center" rowspan="1" colspan="1">0.875</td><td align="center" rowspan="1" colspan="1">0.955</td><td align="center" rowspan="1" colspan="1">0.884</td><td align="center" rowspan="1" colspan="1">0.918</td><td align="center" rowspan="1" colspan="1">0.884</td><td align="center" rowspan="1" colspan="1">0.840</td></tr><tr><td align="left" rowspan="1" colspan="1">Test</td><td align="center" rowspan="1" colspan="1">0.843</td><td align="center" rowspan="1" colspan="1">0.788</td><td align="center" rowspan="1" colspan="1">0.897</td><td align="center" rowspan="1" colspan="1">0.835</td><td align="center" rowspan="1" colspan="1">0.840</td><td align="center" rowspan="1" colspan="1">0.835</td><td align="center" rowspan="1" colspan="1">0.631</td></tr></tbody></table><table-wrap-foot><fn fn-type="other"><p>AUC: area under curve; NPV: negative predictive value; PPV: positive predictive value.</p></fn></table-wrap-foot></table-wrap>
</p></sec><sec><title>Interpretability analysis</title><p>SHAP analysis was conducted to rank the importance of features in the 5-fold cross-validation models to enhance the interpretability of the optimal decision model (Fig. <xref rid="F4" ref-type="fig">4</xref>A). Interestingly, the PHF<sub>S</sub> were more dominant, considering that four of the top-ranked radiomics features in terms of importance were PHF<sub>S</sub>. Furthermore, one case was randomly selected from each of the pCR and non-pCR groups for illustrative purposes. The results revealed that within the pCR group, IHF was ranked highest in terms of importance (Fig. <xref rid="F4" ref-type="fig">4</xref>B). Conversely, in the non-pCR group, PHF held the top position (as depicted in Fig. <xref rid="F4" ref-type="fig">4</xref>C). Given the relatively comparable importance of certain features (as delineated in Supplemental Digital Content, Figure S3, available at: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://links.lww.com/JS9/E434" ext-link-type="uri">http://links.lww.com/JS9/E434</ext-link>), the top three features from each individual cross-validation model were selected for subsequent analysis. The specific features are summarized in Table <xref rid="T4" ref-type="table">4</xref>.<fig position="float" id="F4" orientation="portrait"><label>Figure 4.</label><caption><p>SHAP analysis in the decision model. (A) The SHAP bees-warm plot shows the position or negative effects of each feature on the prediction probability through rad and blue colors on a 5-fold training cohort. SHAP summary plot depicting the global prediction impact of features on the decision model and interaction between features. The importance of features is listed from top to bottom. Each point represents the SHAP value of a patient&#8217;s feature. Dots to the left of the Y-axis increase the likelihood of pCR, while dots to the right decrease the probability of pCR. SHAP, Shapley additive explanations. Patients (B) (pCR) and (C) (non-pCR) were randomly selected from the decision model. The waterfall plot shows that the impact of the ranking features on the model for a specific patient, where red represents a positive impact and blue represents a negative impact. P, peritumoral; I, intratumoral; h, habitat; GLCM, gray-level co-occurrence matrix, GLRLM, gray-level run-length matrix, GLSZM, gray-level size zone matrix, NGTDM, neighborhood gray-tone difference matrix; pCR, pathologic complete response.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="js9-111-6232-g004.jpg"/></fig>
<table-wrap position="float" id="T4" orientation="portrait"><label>Table 4</label><caption><p>Associations between the key radiomic features selected by SHAP and both PD-L1 CPS and CD45+&#160;in the stroma</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2" colspan="1">Radiomics features</th><th align="center" colspan="2" rowspan="1">CPS</th><th align="center" colspan="2" rowspan="1">CD45+</th></tr><tr><th align="center" rowspan="1" colspan="1">t</th><th align="center" rowspan="1" colspan="1"><italic toggle="yes">P</italic></th><th align="center" rowspan="1" colspan="1">r</th><th align="center" rowspan="1" colspan="1"><italic toggle="yes">P</italic></th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">P_T1_h2_Firstorder_Kurtosis</td><td align="center" rowspan="1" colspan="1">&#8722;0.357</td><td align="center" rowspan="1" colspan="1">0.723</td><td align="center" rowspan="1" colspan="1">0.406</td><td align="center" rowspan="1" colspan="1">0.423</td></tr><tr><td align="left" rowspan="1" colspan="1">P_T1C_h2_GLDM_SmallDependence HighGrayLevelEmphasis</td><td align="center" rowspan="1" colspan="1">&#8722;0.339</td><td align="center" rowspan="1" colspan="1">0.736</td><td align="center" rowspan="1" colspan="1">0.958</td><td align="center" rowspan="1" colspan="1">0.003<xref rid="tbl4-fn1" ref-type="table-fn">a</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">P_T1C_h4_Firstorder_Variance</td><td align="center" rowspan="1" colspan="1">&#8722;0.649</td><td align="center" rowspan="1" colspan="1">0.521</td><td align="center" rowspan="1" colspan="1">&#8722;0.919</td><td align="center" rowspan="1" colspan="1">0.009<xref rid="tbl4-fn1" ref-type="table-fn">a</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">P_T1C_h5_ Firstorder _Skewness</td><td align="center" rowspan="1" colspan="1">2.222</td><td align="center" rowspan="1" colspan="1">0.033<xref rid="tbl4-fn1" ref-type="table-fn">a</xref></td><td align="center" rowspan="1" colspan="1">&#8722;0.164</td><td align="center" rowspan="1" colspan="1">0.754</td></tr><tr><td align="left" rowspan="1" colspan="1">P_T2_h1_GLRLM_LongRunHigh GrayLevelEmphasis</td><td align="center" rowspan="1" colspan="1">&#8722;0.813</td><td align="center" rowspan="1" colspan="1">0.422</td><td align="center" rowspan="1" colspan="1">0.343</td><td align="center" rowspan="1" colspan="1">0.504</td></tr><tr><td align="left" rowspan="1" colspan="1">P_T2_h4_GLCM_Contrast</td><td align="center" rowspan="1" colspan="1">&#8722;0.304</td><td align="center" rowspan="1" colspan="1">0.762</td><td align="center" rowspan="1" colspan="1">&#8722;0.224</td><td align="center" rowspan="1" colspan="1">0.668</td></tr><tr><td align="left" rowspan="1" colspan="1">I_T1_h3_Firstorder_Median</td><td align="center" rowspan="1" colspan="1">2.344</td><td align="center" rowspan="1" colspan="1">0.025<xref rid="tbl4-fn1" ref-type="table-fn">a</xref></td><td align="center" rowspan="1" colspan="1">&#8722;0.173</td><td align="center" rowspan="1" colspan="1">0.742</td></tr><tr><td align="left" rowspan="1" colspan="1">I_T1C_h4_Firderorder_Kurtosis</td><td align="center" rowspan="1" colspan="1">0.201</td><td align="center" rowspan="1" colspan="1">0.841</td><td align="center" rowspan="1" colspan="1">&#8722;0.281</td><td align="center" rowspan="1" colspan="1">0.588</td></tr><tr><td align="left" rowspan="1" colspan="1">I_T1C_h4_GLSZM_LargeAreaLowGray LevelEmphasis</td><td align="center" rowspan="1" colspan="1">2.027</td><td align="center" rowspan="1" colspan="1">0.069</td><td align="center" rowspan="1" colspan="1">&#8722;0.102</td><td align="center" rowspan="1" colspan="1">0.846</td></tr><tr><td align="left" rowspan="1" colspan="1">I_T2_h5_Firstorder_10Percentile</td><td align="center" rowspan="1" colspan="1">2.275</td><td align="center" rowspan="1" colspan="1">0.029<xref rid="tbl4-fn1" ref-type="table-fn">a</xref></td><td align="center" rowspan="1" colspan="1">0.131</td><td align="center" rowspan="1" colspan="1">0.804</td></tr><tr><td align="left" rowspan="1" colspan="1">I_T2_h5_Firstorder_RootMean Squared</td><td align="center" rowspan="1" colspan="1">2.233</td><td align="center" rowspan="1" colspan="1">0.032<xref rid="tbl4-fn1" ref-type="table-fn">a</xref></td><td align="center" rowspan="1" colspan="1">0.065</td><td align="center" rowspan="1" colspan="1">0.901</td></tr></tbody></table><table-wrap-foot><fn fn-type="other"><p>h: habitat; I: intratumoral; P: peritumoral; T1: T1-weighted imaging; T1C: contrast-enhanced T1-weighted imaging with fat suppression; T2: axial T2-weighted imaging with fat suppression.</p></fn><fn id="tbl4-fn1"><label><sup>a</sup></label><p>Statistically significant.</p></fn></table-wrap-foot></table-wrap>
</p><p>Further biological interpretability analysis demonstrated that CD45+&#160;white blood cell densities were significantly higher in the stroma of pCR patients compared to non-pCR patients (<italic toggle="yes">P</italic> =&#160;0.03) (Fig. <xref rid="F5" ref-type="fig">5</xref>A-H). Moreover, two PHFs (P_T1C_h2_dm_SmallDependenceHighGrayLevelEmphasis, P_T1C_h4_F_Variance) among the aforementioned features were highly correlated with CD45+&#160;white blood cell densities in the stroma (r&#160;=&#160;0.958,&#160;&#8722;0.920, <italic toggle="yes">P</italic> &lt; 0.05) (Table <xref rid="T4" ref-type="table">4</xref> and Fig <xref rid="F5" ref-type="fig">5</xref>I-J). In addition, this study preliminarily explored the relationship between the aforementioned features and PD-L1 CPS. Three IHFs (I_T1_h3_Firstorder_Median,I_T2_h5_Firstorder_10Percentile, I_T2_h5_Firstorder_RootMeanSquared) and one PHF (P_T1C_h5_Firstorder_Skewness) could distinguish between lower and higher CPS scores (t&#160;=&#160;2.027&#160;~&#160;2.275, <italic toggle="yes">P</italic> &lt; 0.05) (Table <xref rid="T4" ref-type="table">4</xref> and Fig <xref rid="F5" ref-type="fig">5</xref>K-N).<fig position="float" id="F5" orientation="portrait"><label>Figure 5.</label><caption><p>Biological Interpretability Analysis. (A) Pathological specimen section. (B) Hematoxylin&#8211;eosin (H&amp;E) staining. (C&#8211;E) Comparison of CD3+, CD19+,&#160;and CD45+&#160;in tumors between pCR and non-pCR groups. (F&#8211;H) Comparison of CD3+, CD19+,&#160;and CD45+&#160;in stroma between pCR and non-pCR groups. (I) Correlation between P_T1C_h2_GLDM_SmallDependenceHighGrayLevelEmphasi and CD45+&#160;in stroma. (J) Correlation between P_T1C_h4_Firstorder_Variance with CD45+&#160;in stroma. (K&#8211;N) Distribution of radiomic features with statistical significance among patients stratified into different PD-L1 CPS groups. I_T1_h3_Firstorder_Median (K), I_T2_h5_ Firstorder_10Percentile (L), I_T2_h5_ Firstorder_RootMeanSquared (M), P_T1C_h5_ Firstorder_Skewness (N) . Intra, intratumoral; Peri, peritumoral; h, habitat; GLDM, gray-level dependence matrix; T1, T1-weighted imaging; T1C, contrast-enhanced T1-weighted imaging with fat suppression; T2, axial T2-weighted imaging with fat suppression; pCR, pathologic complete response.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="js9-111-6232-g005.jpg"/></fig>
</p></sec></sec><sec sec-type="discussion"><title>Discussion</title><p>To the best of our knowledge, this is the first study to apply multi-parameter MRI-based intratumoral and peritumoral HI to predict pCR following NACI in OSCC patients. As anticipated, the overall efficacy of the peritumoral HI models was marginally higher than that of the intratumoral HI models. The decision model composed of 18 PHFs, 16 IHFs, and 3 clinical features (Number of induction cycles, postT, AGR) achieved the highest efficacy. In terms of biological verification, among the 11 most important features screened by SHAP, 3 ITHs and 1 PTHs were associated with PD-L1 CPS, whilst 2 PTHs were highly correlated with CD45+&#160;white blood in the stroma, which was correlated with pCR.</p><p>Notably, traditional radiomics methods have been extensively applied in OSCC, yet research on predicting the pCR of NACI for OSCC remains extremely limited. Liu <italic toggle="yes">et al</italic>[<xref rid="R14" ref-type="bibr">14</xref>] extracted histogram features from pre- and post-treatment MRI images (T1WI, T2WI, T1C) and ADC maps of HNSCC patients. Their models demonstrated promising predictive ability (AUC&#160;=&#160;0.83), which is lower than that of our models (AUCs&#160;=&#160;0.913 and 0.843 in the training and test sets, respectively). Moreover, the sample size of their study was relatively small, with only 11 out of 24 patients achieving pCR. In another study, Lin <italic toggle="yes">et al</italic>[<xref rid="R12" ref-type="bibr">12</xref>] integrated intratumoral and peritumoral radiomics features derived from T2WI and T1C sequences to predict pCR in HNSCC, achieving high AUC values (0.904, 0.860 and 0.849 in the internal training, test and external validation sets). However, their final model included PD-L1 CPS, which necessitates invasive testing and expensive cost. In contrast, our model does not directly incorporate biomarkers. Instead, we identified intratumoral and peritumoral habitat radiomics features associated with biomarkers such as PD-L1 CPS and CD45+&#160;cell, and used them to develop the decision model. This approach enables our predictive model to have broader applications.</p><p>Furthermore, the integration of ITFs and PTFs into our decision model demonstrated superior predictive performance for pCR in comparison to single intratumoral or peritumoral HI model. It is noteworthy that the peritumoral HI model exhibited a modest advantage over the intratumoral HI model. This result aligns with the findings of previous studies that investigated the prediction of epidermal growth factor receptor (EGFR) mutations[<xref rid="R32" ref-type="bibr">32</xref>], the invasiveness of lung adenocarcinoma[<xref rid="R31" ref-type="bibr">31</xref>], and microvascular invasion in hepatocellular carcinoma[<xref rid="R33" ref-type="bibr">33</xref>]. Intratumoral HI model can elucidate the internal biological behavior of tumors, the integrated model broadens the dimensionality of data by incorporating peritumoral features, enhancing its ability to distinguish between responders and non-responders to immunotherapy. The peritumoral region functions as a critical interface between tumor tissue and normal tissue, contain such as immune cells, blood vessels, fibroblasts, and the extracellular matrix. Research has demonstrated that cells within the peritumoral region, including lymphocytes, dendritic cells, high endothelial venule cells, and myofibroblastic cancer-associated fibroblasts, exert a substantial influence on the immune response to tumor cells[<xref rid="R40" ref-type="bibr">40</xref>]. Concurrently, peritumoral blood vessels, induced by factors such as vascular endothelial growth factor (VEGF), influence drug delivery and immune cell trafficking. Consequently, the intricate tumor microenvironment in the peritumoral area is instrumental in determining the efficacy of immunotherapy. These factors facilitate a more comprehensive reflection of the tumor&#8217;s biological behavior within the peritumoral region, consequently enhancing the performance of predicting pCR. This finding is consistent with the observations reported in previous research<sup>[<xref rid="R31" ref-type="bibr">31</xref>-<xref rid="R33" ref-type="bibr">33</xref>]</sup>.</p><p>In terms of the biological interpretability of imaging features, this study identified, through SHAP analysis, that two PHFs were highly correlated with CD45+&#160;cells in the stroma, while multiple IHFs were associated with the PD-L1 CPS in tumor cells. CD45, a leukocyte marker, encompasses various immune cell subsets, including T lymphocytes, B lymphocytes, macrophages, dendritic cells, and neutrophils. Our findings indicate that CD45+&#160;cells (i.e., leukocytes) in the peritumoral stroma prior to treatment are associated with pCR in OSCC. Higher CD45+&#160;cell density has been demonstrated to be a significant predictor of enhanced immune-tumor interactions and improved responses to immunotherapy in this study. Meanwhile, these PHFs may potentially serve as indicators for monitoring changes in the peritumoral immune microenvironment, providing a novel perspective for evaluating the efficacy of immunotherapy. Numerous studies had demonstrated a positive correlation between higher levels of immune cells, particularly specific CD8+&#160;T cell subsets, and enhanced survival outcomes<sup>[<xref rid="R41" ref-type="bibr">41</xref>,<xref rid="R42" ref-type="bibr">42</xref>]</sup>. Conversely, the PD-L1 CPS in tumor cells functions as a significant biomarker for predicting the efficacy of immunotherapy in head and neck cancer. Patients with higher CPS scores frequently demonstrate superior immune responses[<xref rid="R43" ref-type="bibr">43</xref>]. Also, there are some studies that investigated the microenvironment of HNSCC through the application of radiomics. For instance, Wang <italic toggle="yes">et al</italic>[<xref rid="R44" ref-type="bibr">44</xref>].employed preoperative CT-based radiomics to predict the enrichment status of CD8+&#160;T cells in HNSCC. Katsoulakis <italic toggle="yes">et al</italic>[<xref rid="R4" ref-type="bibr">4</xref>] developed a model to predict CD8+&#160;T cell infiltration in HNSCC through radiomic analysis using data from The Cancer Imaging Archive and The Cancer Genome Atlas. In the present study, IHFs were found to be predominant in a randomly selected patient sample with pCR, and multiple IHFs were correlated with CPS. In a randomly selected non-pCR patient sample, PHFs were found to be predominant. It is imperative that future research endeavors prioritize the execution of expansive sample studies, which are essential for further exploration and elucidation of the underlying phenomena.</p><p>Nevertheless, this study is subject to several limitations. Firstly, as a retrospective study, there are risks of selection and recall bias. Despite the employment of a medium-sized sample, five-fold cross-validation, and stable radiomics features to reduce overfitting[<xref rid="R45" ref-type="bibr">45</xref>], biases may still exist. Furthermore, the performance of the model may be subject to confounding by multiple clinical covariates, including tumor localization and chemotherapy strategy. Therefore, a prospective, multi-center study is required. Secondly, although correlations between tumor microenvironment radiomics features and PD-L1 CPS, CD45+&#160;cells in the stroma were established, further immunological validation at the tissue and molecular level is required. Thirdly, in order to minimize data consistency discrepancies across different centers, the use of functional MRI image such as diffusion weighted imaging (DWI) was excluded. Subsequent research will investigate multi-sequence combinations to enhance prediction accuracy. Finally, in the absence of a consensus definition of the peritumoral region<sup>[<xref rid="R32" ref-type="bibr">32</xref>,<xref rid="R33" ref-type="bibr">33</xref>,<xref rid="R46" ref-type="bibr">46</xref>]</sup>, it is acknowledged that variations in the definition may have a consequential impact on the performance of the models. Further study was need to conduct an in-depth exploration of the effects of different peritumoral areas on radiomics models, and also investigate the associations between the radiomics features and biomarkers to determine the optimal definition of the peritumoral region.</p><p>In summary, the MR-based integrated intratumoral and peritumoral HI models can provide valuable information for predicting the response to NACI in OSCC, and SHAP interpretability analysis enhances the interpretability of the decision model, thereby enabling the formulation of personalized treatment for patients.
</p></sec></body><back><ack><title>Acknowledgements</title><p>We thank Home for Researchers editorial team (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="www.home-for-researchers.com" ext-link-type="uri">www.home-for-researchers.com</ext-link>) for language editing service.</p></ack><fn-group><fn id="FT0001"><p>Zilong Yuan, Shuangquan Ai, Qing He, Kun Wu contributed equally to this work.</p></fn><fn fn-type="other"><p>Sponsorships or competing interests that may be relevant to content are disclosed at the end of this article.</p></fn><fn fn-type="other"><p>Supplemental Digital Content is available for this article. Direct URL citations are provided in the HTML and PDF versions of this article on the journal&#8217;s website, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="www.lww.com/international-journal-of-surgery" ext-link-type="uri">www.lww.com/international-journal-of-surgery</ext-link>.</p></fn><fn fn-type="equal"><p>Published online 20 June 2025</p></fn></fn-group><sec><title>Ethical approval</title><p>This retrospective study was approved by the Institutional Review Board of Hubei Cancer Hospital, Wuhan, China (approval number: [2024]KYLL(SO4)).</p></sec><sec><title>Consent</title><p>Written informed consent was obtained from the patient for publication of this case report and accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal on request.</p></sec><sec><title>Sources of funding</title><p>Y.L. was supported by Talent Project of Hubei Cancer Hospital (NO:2025HBCHLHRC001), Chutian Talents of Hubei (NO: CTYC001), Hubei Provincial Key Technology Foundation of China (grant no. 2021ACA013). Y.W. was supported by the Talent Project of Hubei Cancer Hospital (grant no. 2025HBCHHHRC006).</p></sec><sec><title>Author contributions</title><p>Z.Y.: conceptualization, methodology, supervision, writing &#8211; original draft; S.A.: data curation, investigation, methodology, software, validation, writing &#8211; review &amp; editing; Q.H.: data curation, investigation, writing &#8211; review &amp; editing; K.W.: data curation, investigation, resources, writing &#8211; review &amp; editing; M.Y.: resources, writing &#8211; review &amp; editing; K.Z.: data curation, methodology; Y.H.: data curation, writing &#8211; review &amp; editing; X.T.: data curation, investigation, supervision, writing &#8211; review &amp; editing; Y.L.: project administration, funding acquisition, writing &#8211; review &amp; editing; Z.W.: data curation, writing &#8211; review &amp; editing; Y.W.: project administration, funding acquisition, writing &#8211; review &amp; editing.</p></sec><sec sec-type="COI-statement"><title>Conflicts of interest disclosure</title><p>The authors declare no conflicts interest.</p></sec><sec><title>Research registration unique identifying number (UIN)</title><p><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT06854107">NCT06854107</ext-link>. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.clinicaltrials.gov/study/NCT06854107?cond=NCT06854107%26rank=1" ext-link-type="uri">https://www.clinicaltrials.gov/study/NCT06854107?cond=NCT06854107&amp;rank=1</ext-link>.</p></sec><sec><title>Guarantor</title><p>Zilong Yuan and Yuan Wu.</p></sec><sec><title>Provenance and peer review</title><p>Not commissioned, externally peer-reviewed.</p></sec><sec sec-type="data-availability"><title>Data availability statement</title><p>All data generated for this study are available from the corresponding author upon reasonable request.</p></sec><ref-list><title>References</title><ref id="R1"><label>[1]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sung</surname><given-names>H</given-names></name><name name-style="western"><surname>Ferlay</surname><given-names>J</given-names></name><name name-style="western"><surname>Siegel</surname><given-names>RL</given-names></name><etal/></person-group>. <article-title>Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries</article-title>. <source>CA Cancer J Clin</source><year>2021</year>;<volume>71</volume>:<fpage>209</fpage>&#8211;<lpage>49</lpage>.<pub-id pub-id-type="pmid">33538338</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3322/caac.21660</pub-id></mixed-citation></ref><ref id="R2"><label>[2]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gatta</surname><given-names>G</given-names></name><name name-style="western"><surname>Botta</surname><given-names>L</given-names></name><name name-style="western"><surname>S&#225;nchez</surname><given-names>MJ</given-names></name><etal/></person-group>. <article-title>Prognoses and improvement for head and neck cancers diagnosed in Europe in early 2000s: the EUROCARE-5 population-based study</article-title>. <source>Eur J Cancer</source><year>2015</year>;<volume>51</volume>:<fpage>2130</fpage>&#8211;<lpage>43</lpage>.<pub-id pub-id-type="pmid">26421817</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ejca.2015.07.043</pub-id></mixed-citation></ref><ref id="R3"><label>[3]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wu</surname><given-names>D</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y</given-names></name><name name-style="western"><surname>Xu</surname><given-names>P</given-names></name><etal/></person-group>. <article-title>Neoadjuvant chemo-immunotherapy with camrelizumab plus nab-paclitaxel and cisplatin in resectable locally advanced squamous cell carcinoma of the head and neck: a pilot phase II trial</article-title>. <source>Nat Commun</source><year>2024</year>;<volume>15</volume>:<fpage>2177</fpage>.<pub-id pub-id-type="pmid">38467604</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41467-024-46444-z</pub-id><pub-id pub-id-type="pmcid">PMC10928200</pub-id></mixed-citation></ref><ref id="R4"><label>[4]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Katsoulakis</surname><given-names>E</given-names></name><name name-style="western"><surname>Yu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Apte</surname><given-names>AP</given-names></name><etal/></person-group>. <article-title>Radiomic analysis identifies tumor subtypes associated with distinct molecular and microenvironmental factors in head and neck squamous cell carcinoma</article-title>. <source>Oral Oncol</source><year>2020</year>;<volume>110</volume>:<fpage>104877</fpage>.<pub-id pub-id-type="pmid">32619927</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.oraloncology.2020.104877</pub-id><pub-id pub-id-type="pmcid">PMC7606635</pub-id></mixed-citation></ref><ref id="R5"><label>[5]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>K</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>Z</given-names></name><name name-style="western"><surname>Wang</surname><given-names>R</given-names></name><etal/></person-group>. <article-title>A multi-objective radiomics model for the prediction of locoregional recurrence in head and neck squamous cell cancer</article-title>. <source>Med Phys</source><year>2020</year>;<volume>47</volume>:<fpage>5392</fpage>&#8211;<lpage>400</lpage>.<pub-id pub-id-type="pmid">32657426</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/mp.14388</pub-id></mixed-citation></ref><ref id="R6"><label>[6]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Keek</surname><given-names>S</given-names></name><name name-style="western"><surname>Sanduleanu</surname><given-names>S</given-names></name><name name-style="western"><surname>Wesseling</surname><given-names>F</given-names></name><etal/></person-group>. <article-title>Computed tomography-derived radiomic signature of head and neck squamous cell carcinoma (peri)tumoral tissue for the prediction of locoregional recurrence and distant metastasis after concurrent chemo-radiotherapy</article-title>. <source>PLoS One</source><year>2020</year>;<volume>15</volume>:<fpage>e0232639</fpage>.<pub-id pub-id-type="pmid">32442178</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0232639</pub-id><pub-id pub-id-type="pmcid">PMC7244120</pub-id></mixed-citation></ref><ref id="R7"><label>[7]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mes</surname><given-names>SW</given-names></name><name name-style="western"><surname>van Velden</surname><given-names>FHP</given-names></name><name name-style="western"><surname>Peltenburg</surname><given-names>B</given-names></name><etal/></person-group>. <article-title>Outcome prediction of head and neck squamous cell carcinoma by MRI radiomic signatures</article-title>. <source>Eur Radiol</source><year>2020</year>;<volume>30</volume>:<fpage>6311</fpage>&#8211;<lpage>21</lpage>.<pub-id pub-id-type="pmid">32500196</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00330-020-06962-y</pub-id><pub-id pub-id-type="pmcid">PMC7554007</pub-id></mixed-citation></ref><ref id="R8"><label>[8]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Leger</surname><given-names>S</given-names></name><name name-style="western"><surname>Zwanenburg</surname><given-names>A</given-names></name><name name-style="western"><surname>Leger</surname><given-names>K</given-names></name><etal/></person-group>. <article-title>Comprehensive analysis of tumour sub-volumes for radiomic risk modelling in locally advanced HNSCC</article-title>. <source>Cancers (Basel)</source><year>2020</year>;<volume>12</volume>:<fpage>3047</fpage>.<pub-id pub-id-type="pmid">33086761</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/cancers12103047</pub-id><pub-id pub-id-type="pmcid">PMC7589463</pub-id></mixed-citation></ref><ref id="R9"><label>[9]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ou</surname><given-names>D</given-names></name><name name-style="western"><surname>Blanchard</surname><given-names>P</given-names></name><name name-style="western"><surname>Rosellini</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>Predictive and prognostic value of CT based radiomics signature in locally advanced head and neck cancers patients treated with concurrent chemoradiotherapy or bioradiotherapy and its added value to Human Papillomavirus status</article-title>. <source>Oral Oncol</source><year>2017</year>;<volume>71</volume>:<fpage>150</fpage>&#8211;<lpage>55</lpage>.<pub-id pub-id-type="pmid">28688683</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.oraloncology.2017.06.015</pub-id></mixed-citation></ref><ref id="R10"><label>[10]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Salvatore</surname><given-names>A</given-names></name><name name-style="western"><surname>Rebecca</surname><given-names>R</given-names></name><name name-style="western"><surname>Marco</surname><given-names>B</given-names></name><etal/></person-group>. <article-title>Prognostic role of pre-treatment magnetic resonance imaging (MRI)-based radiomic analysis in effectively cured head and neck squamous cell carcinoma (HNSCC) patients</article-title>. <source>Acta Oncologica</source><year>2024</year>;<volume>60</volume>:<fpage>1192</fpage>&#8211;<lpage>200</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/0284186X.2021.1924401</pub-id><pub-id pub-id-type="pmid">34038324</pub-id></mixed-citation></ref><ref id="R11"><label>[11]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yoon</surname><given-names>H</given-names></name><name name-style="western"><surname>Ha</surname><given-names>S</given-names></name><name name-style="western"><surname>Kwon</surname><given-names>SJ</given-names></name><etal/></person-group>. <article-title>Prognostic value of tumor metabolic imaging phenotype by FDG PET radiomics in HNSCC</article-title>. <source>Ann Nucl Med</source><year>2021</year>;<volume>35</volume>:<fpage>370</fpage>&#8211;<lpage>77</lpage>.<pub-id pub-id-type="pmid">33554314</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s12149-021-01586-8</pub-id></mixed-citation></ref><ref id="R12"><label>[12]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lin</surname><given-names>P</given-names></name><name name-style="western"><surname>Xie</surname><given-names>W</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y</given-names></name><etal/></person-group>. <article-title>Intratumoral and peritumoral radiomics of MRIs predicts pathologic complete response to neoadjuvant chemoimmunotherapy in patients with head and neck squamous cell carcinoma</article-title>. <source>J Immunother Cancer</source><year>2024</year>;<volume>12</volume>:<fpage>e009616</fpage>.<pub-id pub-id-type="pmid">39500529</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/jitc-2024-009616</pub-id><pub-id pub-id-type="pmcid">PMC11552555</pub-id></mixed-citation></ref><ref id="R13"><label>[13]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yuan</surname><given-names>Y</given-names></name><name name-style="western"><surname>Ren</surname><given-names>J</given-names></name><name name-style="western"><surname>Shi</surname><given-names>Y</given-names></name><etal/></person-group>. <article-title>MRI-based radiomic signature as predictive marker for patients with head and neck squamous cell carcinoma</article-title>. <source>Eur J Radiol</source><year>2019</year>;<volume>117</volume>:<fpage>193</fpage>&#8211;<lpage>98</lpage>.<pub-id pub-id-type="pmid">31307647</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ejrad.2019.06.019</pub-id></mixed-citation></ref><ref id="R14"><label>[14]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>H</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>C</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X</given-names></name><etal/></person-group>. <article-title>Prediction of pathological complete response in locally advanced head and neck squamous cell carcinoma treated with neoadjuvant chemo-immunotherapy using volumetric multisequence MRI histogram analysis</article-title>. <source>Neuroradiology</source><year>2024</year>;<volume>66</volume>:<fpage>919</fpage>&#8211;<lpage>29</lpage>.<pub-id pub-id-type="pmid">38503986</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00234-024-03339-6</pub-id></mixed-citation></ref><ref id="R15"><label>[15]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>W</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y</given-names></name><name name-style="western"><surname>Gao</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>Integrating lipid metabolite analysis with MRI-based transformer and radiomics for early and late stage prediction of oral squamous cell carcinoma</article-title>. <source>BMC Cancer</source><year>2024</year>;<volume>24</volume>:<fpage>795</fpage>&#8211;<lpage>12</lpage>.<pub-id pub-id-type="pmid">38961418</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12885-024-12533-x</pub-id><pub-id pub-id-type="pmcid">PMC11221018</pub-id></mixed-citation></ref><ref id="R16"><label>[16]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>Z</given-names></name><name name-style="western"><surname>Yu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Liu</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>A deep learning and radiomics fusion model based on contrast-enhanced computer tomography improves preoperative identification of cervical lymph node metastasis of oral squamous cell carcinoma</article-title>. <source>Clin Oral Investig</source><year>2023</year>;<volume>28</volume>:<fpage>39</fpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00784-023-05423-2</pub-id><pub-id pub-id-type="pmid">38151672</pub-id></mixed-citation></ref><ref id="R17"><label>[17]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jin</surname><given-names>N</given-names></name><name name-style="western"><surname>Qiao</surname><given-names>B</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Predicting cervical lymph node metastasis in OSCC based on computed tomography imaging genomics</article-title>. <source>Cancer Med</source><year>2023</year>;<volume>12</volume>:<fpage>19260</fpage>&#8211;<lpage>71</lpage>.<pub-id pub-id-type="pmid">37635388</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/cam4.6474</pub-id><pub-id pub-id-type="pmcid">PMC10557859</pub-id></mixed-citation></ref><ref id="R18"><label>[18]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tomita</surname><given-names>H</given-names></name><name name-style="western"><surname>Yamashiro</surname><given-names>T</given-names></name><name name-style="western"><surname>Heianna</surname><given-names>J</given-names></name><etal/></person-group>. <article-title>Nodal-based radiomics analysis for identifying cervical lymph node metastasis at levels I and II in patients with oral squamous cell carcinoma using contrast-enhanced computed tomography</article-title>. <source>Eur Radiol</source><year>2021</year>;<volume>31</volume>:<fpage>7440</fpage>&#8211;<lpage>49</lpage>.<pub-id pub-id-type="pmid">33787970</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00330-021-07758-4</pub-id></mixed-citation></ref><ref id="R19"><label>[19]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>W</given-names></name><name name-style="western"><surname>Liang</surname><given-names>H</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Z</given-names></name><etal/></person-group>. <article-title>Comparing three-dimensional and two-dimensional deep-learning, radiomics, and fusion models for predicting occult lymph node metastasis in laryngeal squamous cell carcinoma based on CT imaging: a multicentre, retrospective, diagnostic study</article-title>. <source>EClinicalMedicine</source><year>2024</year>;<volume>67</volume>:<fpage>102385</fpage>.<pub-id pub-id-type="pmid">38261897</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.eclinm.2023.102385</pub-id><pub-id pub-id-type="pmcid">PMC10796944</pub-id></mixed-citation></ref><ref id="R20"><label>[20]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lan</surname><given-names>T</given-names></name><name name-style="western"><surname>Kuang</surname><given-names>S</given-names></name><name name-style="western"><surname>Liang</surname><given-names>P</given-names></name><etal/></person-group>. <article-title>MRI-based deep learning and radiomics for prediction of occult cervical lymph node metastasis and prognosis in early-stage oral and oropharyngeal squamous cell carcinoma: a diagnostic study</article-title>. <source>Int J Surg</source><year>2024</year>;<volume>110</volume>:<fpage>4648</fpage>&#8211;<lpage>59</lpage>.<pub-id pub-id-type="pmid">38729119</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/JS9.0000000000001578</pub-id><pub-id pub-id-type="pmcid">PMC11325978</pub-id></mixed-citation></ref><ref id="R21"><label>[21]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ling</surname><given-names>X</given-names></name><name name-style="western"><surname>Alexander</surname><given-names>GS</given-names></name><name name-style="western"><surname>Molitoris</surname><given-names>J</given-names></name><etal/></person-group>. <article-title>Radiomic biomarkers of locoregional recurrence: prognostic insights from oral cavity squamous cell carcinoma preoperative CT scans</article-title>. <source>Front Oncol</source><year>2024</year>;<volume>14</volume>:<fpage>1380599</fpage>.<pub-id pub-id-type="pmid">38715772</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fonc.2024.1380599</pub-id><pub-id pub-id-type="pmcid">PMC11074368</pub-id></mixed-citation></ref><ref id="R22"><label>[22]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>&#214;zt&#252;rk</surname><given-names>EMA</given-names></name><name name-style="western"><surname>&#220;nsal</surname><given-names>G</given-names></name><name name-style="western"><surname>Eri&#351;ir</surname><given-names>F</given-names></name><etal/></person-group>. <article-title>Prediction of bone invasion of oral squamous cell carcinoma using a magnetic resonance imaging-based machine learning model</article-title>. <source>Eur Arch Otorhinolaryngol</source><year>2024</year>;<volume>281</volume>:<fpage>6585</fpage>&#8211;<lpage>97</lpage>.<pub-id pub-id-type="pmid">39083062</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00405-024-08862-z</pub-id><pub-id pub-id-type="pmcid">PMC11564286</pub-id></mixed-citation></ref><ref id="R23"><label>[23]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ling</surname><given-names>X</given-names></name><name name-style="western"><surname>Alexander</surname><given-names>GS</given-names></name><name name-style="western"><surname>Molitoris</surname><given-names>J</given-names></name><etal/></person-group>. <article-title>Identification of CT-based non-invasive radiomic biomarkers for overall survival prediction in oral cavity squamous cell carcinoma</article-title>. <source>Sci Rep</source><year>2023</year>;<volume>13</volume>:<fpage>21774</fpage>.<pub-id pub-id-type="pmid">38066047</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41598-023-48048-x</pub-id><pub-id pub-id-type="pmcid">PMC10709435</pub-id></mixed-citation></ref><ref id="R24"><label>[24]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>DH</given-names></name><name name-style="western"><surname>Park</surname><given-names>JE</given-names></name><name name-style="western"><surname>Kim</surname><given-names>N</given-names></name><etal/></person-group>. <article-title>Tumor habitat analysis using longitudinal physiological MRI to predict tumor recurrence after stereotactic radiosurgery for brain metastasis</article-title>. <source>Korean J Radiol</source><year>2023</year>;<volume>24</volume>:<fpage>235</fpage>&#8211;<lpage>46</lpage>.<pub-id pub-id-type="pmid">36788768</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3348/kjr.2022.0492</pub-id><pub-id pub-id-type="pmcid">PMC9971843</pub-id></mixed-citation></ref><ref id="R25"><label>[25]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>M</given-names></name><name name-style="western"><surname>Park</surname><given-names>JE</given-names></name><name name-style="western"><surname>Yoon</surname><given-names>SK</given-names></name><etal/></person-group>. <article-title>Vessel size and perfusion-derived vascular habitat refines prediction of treatment failure to bevacizumab in recurrent glioblastomas: validation in a prospective cohort</article-title>. <source>Eur Radiol</source><year>2023</year>;<volume>33</volume>:<fpage>4475</fpage>&#8211;<lpage>85</lpage>.<pub-id pub-id-type="pmid">36242633</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00330-022-09164-w</pub-id></mixed-citation></ref><ref id="R26"><label>[26]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wu</surname><given-names>J</given-names></name><name name-style="western"><surname>Gensheimer</surname><given-names>MF</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>N</given-names></name><etal/></person-group>. <article-title>Tumor subregion evolution-based imaging features to assess early response and predict prognosis in oropharyngeal cancer</article-title>. <source>J Nucl Med</source><year>2020</year>;<volume>61</volume>:<fpage>327</fpage>&#8211;<lpage>36</lpage>.<pub-id pub-id-type="pmid">31420498</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2967/jnumed.119.230037</pub-id><pub-id pub-id-type="pmcid">PMC7067523</pub-id></mixed-citation></ref><ref id="R27"><label>[27]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xie</surname><given-names>C</given-names></name><name name-style="western"><surname>Yang</surname><given-names>P</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>X</given-names></name><etal/></person-group>. <article-title>Sub-region based radiomics analysis for survival prediction in oesophageal tumours treated by definitive concurrent chemoradiotherapy</article-title>. <source>EBioMedicine</source><year>2019</year>;<volume>44</volume>:<fpage>289</fpage>&#8211;<lpage>97</lpage>.<pub-id pub-id-type="pmid">31129097</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ebiom.2019.05.023</pub-id><pub-id pub-id-type="pmcid">PMC6606893</pub-id></mixed-citation></ref><ref id="R28"><label>[28]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wu</surname><given-names>J</given-names></name><name name-style="western"><surname>Cao</surname><given-names>G</given-names></name><name name-style="western"><surname>Sun</surname><given-names>X</given-names></name><etal/></person-group>. <article-title>Intratumoral spatial heterogeneity at perfusion MR imaging predicts recurrence-free survival in locally advanced breast cancer treated with neoadjuvant chemotherapy</article-title>. <source>Radiology</source><year>2018</year>;<volume>288</volume>:<fpage>26</fpage>&#8211;<lpage>35</lpage>.<pub-id pub-id-type="pmid">29714680</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1148/radiol.2018172462</pub-id><pub-id pub-id-type="pmcid">PMC6029132</pub-id></mixed-citation></ref><ref id="R29"><label>[29]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Braman</surname><given-names>N</given-names></name><name name-style="western"><surname>Prasanna</surname><given-names>P</given-names></name><name name-style="western"><surname>Whitney</surname><given-names>J</given-names></name><etal/></person-group>. <article-title>Association of peritumoral radiomics with tumor biology and pathologic response to preoperative targeted therapy for HER2 (ERBB2)-positive breast cancer</article-title>. <source>JAMA Network Open</source><year>2019</year>;<volume>2</volume>:<fpage>e192561</fpage>.<pub-id pub-id-type="pmid">31002322</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jamanetworkopen.2019.2561</pub-id><pub-id pub-id-type="pmcid">PMC6481453</pub-id></mixed-citation></ref><ref id="R30"><label>[30]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jiang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Wang</surname><given-names>H</given-names></name><name name-style="western"><surname>Wu</surname><given-names>J</given-names></name><etal/></person-group>. <article-title>Noninvasive imaging evaluation of tumor immune microenvironment to predict outcomes in gastric cancer</article-title>. <source>Ann Oncol</source><year>2020</year>;<volume>31</volume>:<fpage>760</fpage>&#8211;<lpage>68</lpage>.<pub-id pub-id-type="pmid">32240794</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.annonc.2020.03.295</pub-id></mixed-citation></ref><ref id="R31"><label>[31]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zeng</surname><given-names>Y</given-names></name><name name-style="western"><surname>Luo</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>Habitat imaging with tumoral and peritumoral radiomics for prediction of lung adenocarcinoma invasiveness on preoperative chest CT: a multicenter study</article-title>. <source>AJR Am J Roentgenol</source><year>2024</year>;<volume>223</volume>:<fpage>e2431675</fpage>.<pub-id pub-id-type="pmid">39140631</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2214/AJR.24.31675</pub-id></mixed-citation></ref><ref id="R32"><label>[32]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Chen</surname><given-names>W</given-names></name><name name-style="western"><surname>Li</surname><given-names>G</given-names></name><etal/></person-group>. <article-title>Computed Tomography-derived intratumoral and peritumoral radiomics in predicting EGFR mutation in lung adenocarcinoma</article-title>. <source>Radiol Med</source><year>2023</year>;<volume>128</volume>:<fpage>1483</fpage>&#8211;<lpage>96</lpage>.<pub-id pub-id-type="pmid">37749461</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s11547-023-01722-6</pub-id><pub-id pub-id-type="pmcid">PMC10700425</pub-id></mixed-citation></ref><ref id="R33"><label>[33]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>C</given-names></name><name name-style="western"><surname>Wu</surname><given-names>F</given-names></name><name name-style="western"><surname>Wang</surname><given-names>F</given-names></name><etal/></person-group>. <article-title>The association between tumor radiomic analysis and peritumor habitat-derived radiomic analysis on gadoxetate disodium-enhanced MRI with microvascular invasion in hepatocellular carcinoma</article-title>. <source>J Magn Reson Imaging</source><year>2025</year>;<volume>61</volume>:<fpage>1428</fpage>&#8211;<lpage>39</lpage>.<pub-id pub-id-type="pmid">38997242</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/jmri.29523</pub-id></mixed-citation></ref><ref id="R34"><label>[34]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Agha</surname><given-names>RA</given-names></name><name name-style="western"><surname>Mathew</surname><given-names>G</given-names></name><name name-style="western"><surname>Rashid</surname><given-names>R</given-names></name><etal/></person-group>. <article-title>Transparency in the reporting of artificial intelligence &#8211; the TITAN guideline</article-title>. <source>Premier J Sci</source><year>2025</year>;<volume>10</volume>:<fpage>100082</fpage>.</mixed-citation></ref><ref id="R35"><label>[35]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>McShane</surname><given-names>LM</given-names></name><name name-style="western"><surname>Altman</surname><given-names>DG</given-names></name><name name-style="western"><surname>Sauerbrei</surname><given-names>W</given-names></name><etal/></person-group>. <article-title>REporting recommendations for tumour MARKer prognostic studies (REMARK)</article-title>. <source>Br J Cancer</source><year>2005</year>;<volume>93</volume>:<fpage>387</fpage>&#8211;<lpage>91</lpage>.<pub-id pub-id-type="pmid">16106245</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/sj.bjc.6602678</pub-id><pub-id pub-id-type="pmcid">PMC2361579</pub-id></mixed-citation></ref><ref id="R36"><label>[36]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dextraze</surname><given-names>K</given-names></name><name name-style="western"><surname>Saha</surname><given-names>A</given-names></name><name name-style="western"><surname>Kim</surname><given-names>D</given-names></name><etal/></person-group>. <article-title>Spatial habitats from multiparametric MR imaging are associated with signaling pathway activities and survival in glioblastoma</article-title>. <source>Oncotarget</source><year>2017</year>;<volume>8</volume>:<fpage>112992</fpage>&#8211;<lpage>3001</lpage>.<pub-id pub-id-type="pmid">29348883</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.18632/oncotarget.22947</pub-id><pub-id pub-id-type="pmcid">PMC5762568</pub-id></mixed-citation></ref><ref id="R37"><label>[37]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ikoma</surname><given-names>Y</given-names></name><name name-style="western"><surname>Kishimoto</surname><given-names>R</given-names></name><name name-style="western"><surname>Tachibana</surname><given-names>Y</given-names></name><etal/></person-group>. <article-title>Reference region extraction by clustering for the pharmacokinetic analysis of dynamic contrast-enhanced MRI in prostate cancer</article-title>. <source>Magn Reson Imaging</source><year>2020</year>;<volume>66</volume>:<fpage>185</fpage>&#8211;<lpage>92</lpage>.<pub-id pub-id-type="pmid">31487532</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.mri.2019.08.034</pub-id></mixed-citation></ref><ref id="R38"><label>[38]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>K</given-names></name><name name-style="western"><surname>Sui</surname><given-names>C</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Z</given-names></name><etal/></person-group>. <article-title>Habitat radiomics based on CT images to predict survival and immune status in hepatocellular carcinoma, a multi-cohort validation study</article-title>. <source>Transl Oncol</source><year>2025</year>;<volume>52</volume>:<fpage>102260</fpage>.<pub-id pub-id-type="pmid">39752907</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.tranon.2024.102260</pub-id><pub-id pub-id-type="pmcid">PMC11754828</pub-id></mixed-citation></ref><ref id="R39"><label>[39]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kohavi</surname><given-names>R</given-names></name></person-group>. <article-title>A study of cross-validation and bootstrap for accuracy estimation and model selection</article-title>. <source>In Ijcai</source><year>1995</year>;<volume>14</volume>:<fpage>1137</fpage>&#8211;<lpage>45</lpage>.</mixed-citation></ref><ref id="R40"><label>[40]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>YT</given-names></name><name name-style="western"><surname>Liu</surname><given-names>HM</given-names></name><name name-style="western"><surname>Ren</surname><given-names>JG</given-names></name><etal/></person-group>. <article-title>Immune-featured stromal niches associate with response to neoadjuvant immunotherapy in oral squamous cell carcinoma</article-title>. <source>Cell Rep Med</source><year>2025</year>;<volume>6</volume>:<fpage>102024</fpage>.<pub-id pub-id-type="pmid">40107247</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.xcrm.2025.102024</pub-id><pub-id pub-id-type="pmcid">PMC11970382</pub-id></mixed-citation></ref><ref id="R41"><label>[41]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhao</surname><given-names>M</given-names></name><name name-style="western"><surname>Schoenfeld</surname><given-names>JD</given-names></name><name name-style="western"><surname>Egloff</surname><given-names>AM</given-names></name><etal/></person-group>. <article-title>T cell dynamics with neoadjuvant immunotherapy in head and neck cancer</article-title>. <source>Nat Rev Clin Oncol</source><year>2025</year>;<volume>22</volume>:<fpage>83</fpage>&#8211;<lpage>94</lpage>.<pub-id pub-id-type="pmid">39658611</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41571-024-00969-w</pub-id></mixed-citation></ref><ref id="R42"><label>[42]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ren</surname><given-names>S</given-names></name><name name-style="western"><surname>Lan</surname><given-names>T</given-names></name><name name-style="western"><surname>Wu</surname><given-names>F</given-names></name><etal/></person-group>. <article-title>Intratumoral CD103+ CD8+ T cells predict response to neoadjuvant chemoimmunotherapy in advanced head and neck squamous cell carcinoma</article-title>. <source>Cancer Commun (Lond)</source><year>2023</year>;<volume>43</volume>:<fpage>1143</fpage>&#8211;<lpage>63</lpage>.<pub-id pub-id-type="pmid">37658605</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/cac2.12480</pub-id><pub-id pub-id-type="pmcid">PMC10565384</pub-id></mixed-citation></ref><ref id="R43"><label>[43]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Burtness</surname><given-names>B</given-names></name><name name-style="western"><surname>Rischin</surname><given-names>D</given-names></name><name name-style="western"><surname>Greil</surname><given-names>R</given-names></name><etal/></person-group>. <article-title>Pembrolizumab alone or with chemotherapy for recurrent/metastatic head and neck squamous cell carcinoma in KEYNOTE-048: subgroup analysis by programmed death ligand-1 combined positive score</article-title>. <source>J Clin Oncol</source><year>2022</year>;<volume>40</volume>:<fpage>2321</fpage>&#8211;<lpage>32</lpage>.<pub-id pub-id-type="pmid">35333599</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1200/JCO.21.02198</pub-id><pub-id pub-id-type="pmcid">PMC9287281</pub-id></mixed-citation></ref><ref id="R44"><label>[44]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>CY</given-names></name><name name-style="western"><surname>Ginat</surname><given-names>DT</given-names></name></person-group>. <article-title>Preliminary computed tomography radiomics model for predicting pretreatment CD8+ T-cell infiltration status for primary head and neck squamous cell carcinoma</article-title>. <source>J Comput Assist Tomogr</source><year>2021</year>;<volume>45</volume>:<fpage>629</fpage>&#8211;<lpage>36</lpage>.<pub-id pub-id-type="pmid">34519454</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/RCT.0000000000001149</pub-id></mixed-citation></ref><ref id="R45"><label>[45]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tunali</surname><given-names>I</given-names></name><name name-style="western"><surname>Hall</surname><given-names>LO</given-names></name><name name-style="western"><surname>Napel</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>Stability and reproducibility of computed tomography radiomic features extracted from peritumoral regions of lung cancer lesions</article-title>. <source>Med Phys</source><year>2019</year>;<volume>46</volume>:<fpage>5075</fpage>&#8211;<lpage>85</lpage>.<pub-id pub-id-type="pmid">31494946</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/mp.13808</pub-id><pub-id pub-id-type="pmcid">PMC6842054</pub-id></mixed-citation></ref><ref id="R46"><label>[46]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vaidya</surname><given-names>P</given-names></name><name name-style="western"><surname>Bera</surname><given-names>K</given-names></name><name name-style="western"><surname>Patil</surname><given-names>PD</given-names></name><etal/></person-group>. <article-title>Novel, non-invasive imaging approach to identify patients with advanced non-small cell lung cancer at risk of hyperprogressive disease with immune checkpoint blockade</article-title>. <source>J Immunother Cancer</source><year>2020</year>;<volume>8</volume>:<fpage>e001343</fpage>.<pub-id pub-id-type="pmid">33051342</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/jitc-2020-001343</pub-id><pub-id pub-id-type="pmcid">PMC7555103</pub-id></mixed-citation></ref></ref-list></back></article></pmc-articleset>